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We see only what we look for. 
We look for only what we know. (Goethe) 
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ABSTRACT 
TITLE: Determination of risk factors for the development of tuberculosis with 
drug-resistant strains of Mycobacterium tuberculosis in the Arkhangelsk 
oblast, Russia. 
RESEARCHER: Olga Toungoussova 
SUPERVISORS: M.D., Ph.D., Professor Gunnar Bjune; Ph.D., Professor Do-
minique A. Caugant; M.D. Per Sandven; M.D., Ph.D., Professor Andrey Mari-
andyshev. 
The financial support was provided by grant no. 49711 from the Norwegian 
Ministry of Health and Social Affaires to PS and by the Norwegian Research 
Council, grant no. 128083/730 to DAC. 
The results of the present study were presented at The International Meeting 
Combating Infectious Diseases in the Baltic Sea and Barents Regions, Sig-
tuna, Sweeden, January 31-Febryary 2 2000; The First Annual Students Con-
ference, University of Bergen, Bergen, Norway, May 2000; Annual Confer-
ence at the Institute of Public Health, Oslo, Norway, December 2000; and The 
Second Annual Students Conference, University of Bergen, Bergen, Norway, 
May 2001. 
DESCRIPTION OF THE PROJECT:  
SETTING: Arkhangelsk, Russia, 1998-2000. 
OBJECTIVE: To study M. tuberculosis resistance to anti-tuberculosis drugs in 
the Arkhangelsk oblast; and to reveal risk factors for the development of drug-
resistant tuberculosis. 
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DESIGN: Strains isolated from 119 patients with pulmonary tuberculosis were 
studied by the BACTEC method. Medical records of the patients were re-
viewed, retrospectively, to identify factors associated with drug resistance. 
RESULTS: Sixty-seven strains (56.3%) were resistant to at least one anti-
tuberculosis drug. Thirty of the 119 strains (25.2%) were multi-drug resistant. 
All strains resistant to rifampicin were multi-drug resistant. Multidrug resis-
tance was four times more common among previously treated patients than 
among new patients. The highest rates of drug resistance were observed for 
streptomycin and isoniazid. 40.4% and 66.7% of strains collected from new 
and previously treated patients were resistant to streptomycin, respectively. 
37.1% and 73.3% of strains collected from new and previously treated pa-
tients were resistant to isoniazid, respectively. A history of previous or inter-
rupted treatment for tuberculosis and being female were significantly associ-
ated with resistance to at least one anti-tuberculosis drug and multi-drug resis-
tance. 
CONCLUSION: Drug-resistant tuberculosis is an important problem in the 
Arkhangelsk oblast, Russia. The spread of drug-resistant strains of M. tuber-
culosis is attributed to several risk factors. A history of previous or interrupted 
treatment for tuberculosis and being female are significantly associated with 
resistance to at least one anti-tuberculosis drug and multidrug resistance. 
Employment in the health sector of Arkhangelsk was significantly associated 
with the development of drug resistance. 
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AIDS  acquired immune deficiency syndrome 
ARTD Arkhangelsk Regional Tuberculosis Dispensary, Arkhangelsk, 
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INTRODUCTION 
The modern era of tuberculosis (TB) began in the mid-1980s. At that 
time it was realised that TB had not only stopped to decline in many 
developed countries but was actually increasing. It was realised that the 
disease was out of control across most of the poorest countries of the world. It 
was for this reason that in 1993 the World Health Organisation (WHO) 
declared TB to be a global emergency.1 
Globally, it is estimated that approximately one-third of the global 
population is infected with Mycobacterium tuberculosis and that 7 to 8 million 
new cases of TB occur each year. WHO has estimated that the total number 
of cases in the world will rise from 7.5 million in 1990 to 10.2 million in the 
year 2000.2-4 Despite of being a treatable and preventable disease, TB kills an 
estimated 2 million people during each year. If TB control will not be further 
strengthened nearly 1 billion people will be newly infected, 200 million people 
will get sick, and 35 million will die from TB between 2000 and 2020.5 TB is a 
leading infectious cause of death among people older than 5 years. Around 
6% of all deaths worldwide are attributed to TB.6-8 It is expected that TB will 
remain one of the 10 leading causes of mortality and morbidity in the world. 
Most of the TB cases and deaths from TB occur in developing coun-
tries. Increases in TB incidence have been observed in developed countries 
as well. In recent years, TB has become confined to definable population 
groups, such as immigrants from countries with a high prevalence of TB, eld-
erly people, substance abusers, homeless, persons in correctional facilities 
and nursing homes. A high incidence of the disease is not unexpected in 
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these groups. Stress and low body weight are more common among home-
less, substance abusers and elderly people and they have been reported to 
increase the risk of TB. 
Factors associated with the resurgence of TB in many countries include 
the human immunodeficiency virus (HIV) epidemic, immigration from endemic 
areas, urban homelessness, drug abuse and insufficient attention to national 
TB control programme.2 
The resurgence of TB has been accompanied by rising drug 
resistance. The spread of M. tuberculosis drug-resistant strains is one of the 
most actual problems in infectious diseases. World community is anxious 
about the possibility of the development of dangerous multi-drug resistant TB, 
that is resistance to at least rifampicin (R) and isoniazid (H). 
Drug-resistant TB is alarming for several reasons. Infection with drug-
resistant M. tuberculosis can give rise to practically untreatable forms of the 
disease. There are only a few effective drugs available for the treatment. 
Treatment of a patient with drug-resistant especially multi-drug resistant TB 
should include second line drugs that are less effective, have more side 
effects and are more expensive. Treatment of drug-resistant TB must be 
individualised and based on the patient’s medication history and results of 
susceptibility test. 
The multi-drug resistant TB can cause many deaths. Patients infected 
with resistant especially multi-drug resistant strains are less likely to be cured, 
especially if they are co-infected with HIV or malnourished. 
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The resurgence of TB and wide spread of drug-resistant TB in Russia 
was attributed to decreased life standard of the population, socio-economical 
changes in the country and unsatisfactory national TB control programme.9 
  
 
18
CHAPTER I 
LITERATURE REVIEW 
Global TB epidemiology, reasons for TB increase 
Most of TB cases and deaths in the world occur in poor countries. 
Increase of TB incidence has been observed in developed countries as well. 
In industrialised countries, more than 80% of individuals infected with M. 
tuberculosis are over the age of 50. By contrast, in the developing world, over 
75% of TB cases are found in individuals below the age of 50, the most 
economically productive age group.10 
The global increase of TB incidence has been observed since the mid-
1980s. There are four principal reasons for this. 
Demographic factors have played a major role in the global re-
emergence of TB. Childhood mortality rates have declined much more rapidly 
than birth rates over the past 30 years, resulting in dramatic increase in the 
size of adolescents and young adult population in the world. The populations 
mostly of poor countries have increased. The highest incidence of TB across 
the world are in central Africa and Southern Asia, particularly in India, where 
the population increase is known to be the most rapid. Current annual 
population growth in these countries is about 100 million, which means that 
global TB incidence in absolute numbers will continue to increase by around 
100.000 cases every year.2 
Factors associated with the resurgence of TB in many countries include 
HIV epidemic. It is known that co-infection with HIV increases the risk of TB 
infection developing into disease by a 100 fold. Infection with HIV leads to ex-
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tensive destruction of the immune defence mechanisms of the body. As a re-
sult, those infected with HIV become ill with severe and often deadly diseases 
to which persons without HIV infection would not usually be susceptible. In 
countries with high TB prevalence, HIV infection is the most important factor 
making a person liable to get clinical TB. Among people already infected with 
TB their life time risk of clinical TB is about 50% if they have been infected 
with HIV. This compares with a 5-10% risk if they are HIV negative. In addition 
HIV infection elevates the risk of rapid progression from primary infection to 
the disease. HIV infection has led to increase of TB incidence especially in 
young and middle-aged adults and it has also caused sharp increase in TB 
case fatality rates particularly in the absence of effective case manage-
ment.2,11,12 
Social and economic trends have also contributed to the spread of TB. 
Over the past 10 years the number of less developed countries has doubled 
while gross national product in some middle-income countries has decreased. 
This has meant a decrease in the availability of resources for TB control pro-
grammes. Population movement in the form of migration of labour, general 
migration, armed conflicts and refugee movement is more common to take 
place nowadays than at any other time in history. It facilitates the increase of 
TB transmission. In recent years, TB has become confined to definable popu-
lation groups, such as disadvantaged populations, immigrants from countries 
with a high prevalence of TB, refugees, displaced, the elderly, homeless, sub-
stance abusers, persons in correctional facilities and nursing homes. A high 
incidence of the disease in these groups is not unexpected because the rates 
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of TB are higher in lower socio-economic groups. Poverty leads to bad and 
overcrowded housing or poor work conditions. These may lower defences as 
well as making infection more likely. People living in these conditions are often 
badly nourished, suffer from alcohol abuse or drug addiction. The whole com-
plex of poverty makes it easier for the M. tuberculosis to cause the dis-
ease.2,11,13 
During the past 4 decades national TB control programmes have failed 
to reduce TB transmission. Health policies in most low and middle-income 
countries have not given priority to TB control. Inadequately funded 
programmes have led to an increase in the pool of chronic infectious 
sources.11 The overwhelming problem with the treatment of TB is that cure 
takes months of treatment. The great majority of TB patients in the world have 
poor health care facilities. Therefore patients do not complete their treatment. 
Premature stop of the treatment for TB results in relapse and the emergence 
of drug resistance. 
 
TB epidemiology in Russia 
During the 19th century the TB epidemic in Western Europe was called 
“The Great White Plague” because it killed up to 25% of the European popula-
tion. At that time TB was practically unknown in Russia. The first cases were 
not reported until 1865, except those travelling to Western Europe. After a 
steadily increase, the TB epidemic in Russia reached its peak during the 
World War I (1914-1917), when about 2 million people, or about 2% of the 
population, died from TB.14 Subsequently, the prevalence of TB dramatically 
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declined in Russia, as well as in other parts of the former Soviet Union. Rus-
sian experts attributed this decline to the government sponsored TB control 
programme introduced in the 1920s.15 
The state government actively supported measures for TB prevention 
and treatment. The first system to combat TB – a dispensary system for TB 
prevention and treatment – was established in 1918. All anti-tuberculosis or-
ganisations and institutions were nationalised in 1922. Eventually a central-
ised TB control system was established.16 
The analysis of the main epidemiological rates of TB in Russia from 
1965 has allowed to reveal different tendencies in the dynamics. The 
incidence rate in 1965 was 119.0/100.000 (excluding the prison system). It 
was decreasing until 1991. After that time a tendency of increasing incidence 
and mortality rate of TB has been observed. The incidence rate has increased 
from 34.0/100.000 (excluding the prison system) in 1991 to 85.2/100.000 
(including the prison system) in 1999.16 The same tendency was observed for 
the mortality rate. It increased from 8.1/100.000 in 1991 to 16.5/100.000 in 
1999. 
In the Arkhangelsk oblast, the incidence of TB in 1965 was 
119.0/100.000 (excluding the prison system), and it was decreasing until 
1991. After that time the incidence rate increased from 20.7/100.000 in 1991 
to 104.0/100.000 (including the prison system) in 2000. The mortality rate has 
also increased from 3.6 to 16.5/100.000 during the same time period. 
Rates nearly hundred times higher have been recorded in prisons. The 
epidemiological implications of TB in prisons in the republics of the former So-
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viet Union may be more serious than commonly assumed.17 Data from 
Marinsk (Siberia), Russia, indicated that a third of patients with TB had been 
in prison. A similar trend was observed in the Ivanovo oblast, Russia. About 
100.000 people confined within the Russian prison system have been diag-
nosed active TB. About 40.000 of them had multidrug resistance (MDR). 
Every year the prison system of Russia releases 30.000 people into the com-
munity with active TB – about 12.000 of them with multi-drug resistant TB.18 
Prisoners in countries of the former Soviet Union including Russia, like 
those in other parts of the world, are at increased risk for TB for several rea-
sons. Prisoners usually come from underprivileged backgrounds and are 
therefore more likely to be infected with M. tuberculosis or even developed TB 
before entering prison. Poor hygiene, malnutrition, inadequate ventilation and 
overcrowding inside prisons provide the ideal conditions for TB spread. Pris-
oners and former prisoners may have an important role in TB transmission, 
particularly of multi-drug resistant forms in the community.17,19,20 
The increase of TB incidence in Russia and former Soviet Union is not 
associated with the HIV epidemic and demographic factors. It is a matter of 
fact that increase of TB rates observed during the past 10 years in Russia was 
not associated with the HIV epidemic. The increase of TB in Russia is rather 
due to poverty, malnutrition and social dislocation.20  
Disintegration of the Soviet Union occurred in 1991. As a result 15 sov-
ereign states or countries and Russian Federation among them appeared. 
The beginning of the next 1992 year was marked by great political and eco-
nomical changes. Great changes in Russia have began in socio-political sys-
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tem, society structure, agency of power and administration, consciousness of 
Russian citizens and economy of the country. These changes resulted in deep 
social and economical crises. The crises led to decreased general reactivity of 
the population and therefore created conditions for wide spread of infectious 
diseases and TB among them.21 
The economical crises happened in Russia in August 1998 has played 
an important role in the increase of TB epidemiological rates for the past 2 
years and has created additional risk for the development of TB epidemic. The 
full-scale financial crisis, which burst out in August, had a clearly expressed 
political nature. It was a result of an inability of all the Russian governments 
between 1995-1998 to provide a balanced state budget through democratic 
procedures for mobilising a consensus of interests. In August 1998, there was 
a sharp jump of consumer price growth. The actual devaluation of the ruble 
after August 17 led to a proportional growth of prices for foods. The population 
in the majority of the Russian cities activated purchases of these goods ex-
pecting a further devaluation of the ruble and shortage of imported goods. The 
crises have impoverished population resulting in malnutrition and deteriorating 
living conditions.20 
During the past 15 years national TB control programme in Russia was 
not given priority because the tendency of decreasing of TB epidemiological 
rates has been observed since the beginning of 1970s. As a result, it led to 
insufficient financial support for medical structures for TB diagnosis and 
treatment. Financial problems resulted in the unavailability of quality drugs 
and irregular drug supply. The budget cuts in medical service led to inade-
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quate treatment of the disease. Inadequate supply of drugs and the subse-
quent inability to offer a full course of treatment has led to the development of 
drug-resistant and multi-drug resistant TB, doubling in civilian communities 
from 3% to 6%, while the rate in prisons was 40%.22,23 
 
Drug-resistant TB 
The resistance of certain M. tuberculosis strains to anti-tuberculosis 
drugs is not a new phenomenon. It was noted when streptomycin (S) was first 
used as monotherapy for TB in the 1940s. The development of multi-drug 
treatment regimens in the 1950s offered a way to overcome the problem. 
From the 1950s through the 1980s the frequency of the transmission of drug-
resistant organisms was thought to be low. It was not until the early 1990s 
when outbreaks of multi-drug resistant TB were reported in patients with HIV 
infection in the United States and Europe, and the problem received interna-
tional attention.7,8,13,24-30 
The spread of M. tuberculosis drug-resistant strains is one of the most 
acute problems in infectious diseases. Drug-resistant TB is alarming for sev-
eral reasons. First, there are only a few effective drugs available. Infection 
with drug-resistant strain can give rise to potentially untreatable form of the 
disease. Second, although only about 5% of immunocompetent population 
infected with M. tuberculosis succumb to the disease, nevertheless, the dis-
ease is highly contagious.19,31 
Drug resistance is divided into two types: primary and secondary (or 
acquired) resistance. 
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Primary resistance is defined as resistance in persons who have never 
received anti-tuberculosis drugs for more than 1 month.32 These patients are 
initially infected with drug-resistant strains. 
Acquired resistance is defined as resistance to anti-tuberculosis drugs, 
which arises during treatment due to poor compliance or improper manage-
ment.4,32  
Adult patients can be infected with primary drug-resistant strain or 
acquire resistance to anti-tuberculosis drugs during the treatment. Usually, 
children have primary resistance, as they get infected from adult source with 
drug-resistant TB.33,34 
The terms acquired drug resistance and primary drug resistance sug-
gest that the exact causative nature of drug resistance is known. Patients may 
not disclose prior treatment for TB due to several reasons. If this occurs, the 
term primary drug resistance may be used inappropriately, as resistance may 
have been acquired during previous concealed treatment. On the other hand, 
patients who fail treatment may do so because their strain was initially resis-
tant to anti-tuberculosis drugs and not because it acquired resistance during 
the treatment. That is why the WHO and International Union Against Tubercu-
losis and Lung Diseases (IUATLD) recommend to use terms drug resistance 
among new cases and drug resistance among previously treated cases.22 
Drug resistance among new cases (formerly: primary drug resistance) 
is the presence of drug-resistant strain of M. tuberculosis in a newly diag-
nosed patient who has never received anti-tuberculosis drugs or has received 
them for less than 1 month.22 
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Drug resistance among previously treated cases (formerly: acquired 
drug resistance) is that found in a patient who has previously received at least 
1 month therapy with anti-tuberculosis drugs.22 
The real magnitude of M. tuberculosis drug resistance world-wide is not 
known.35 In 1995, overall primary resistance rates in the world were described 
to be 0-16.9% for H, 0-3.0% for R, 0-4.2% for ethambutol (E) and 0.1-23.5% 
for S.12 Rates of acquired resistance were higher. The spread of multi-drug 
resistant TB was relatively low in most countries where representative studies 
have been conducted. Primary MDR was described to be 0-10.8% and ac-
quired MDR was found to be 0-48.0%.35 
The problem of drug resistance existed in Russia even during the So-
viet era (in the mid-1980s). Rates of drug resistance have significantly in-
creased during the past decade. According to survey from the North-Western 
part of Russia, primary drug resistance to at least one anti-tuberculosis drug 
increased from 17.0% to 24.0% during 1991-1994. Acquired drug resistance 
existed on a remarkable scale in the North-Western Russia even 10 years 
ago, but since that time resistance patterns have gradually shifted towards 
MDR.36,37 
The latest data on TB drug resistance in Russia are described by the 
WHO/IUATLD surveillance and presented in the Table 1.22 
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Table 1  Indicators of TB drug resistance in the Ivanovo and Tomsk oblasts, Russia, presented in the WHO/IUATLD Global 
Project on Anti-tuberculosis Drug Resistance Surveillance, 200022 
Oblast                                        New cases                                                                     Previously treated cases 
                             
                          Resistance to (%)              MDR     Any resistance      Resistance to (%)                    MDR     Any resistance 
                              (%)               (%)                      (%)                (%) 
                      H         R         E         S                                                   H          R           E          S 
 
Tomsk         19.4      7.9      7.0      24.9        6.5              29.0            42.7      31.0      21.1      53.4        26.7             57.8 
Ivanovo       22.1    15.8      9.9      18.0        9.0              32.4            33.3      42.6      29.6      46.3        25.9             68.5 
 
 
MDR = multidrug resistance; Any resistance = resistance to at least one drug; H = isoniazid; R = rifampicin; E = ethambutol; 
S = streptomycin 
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In the Arkhangelsk oblast, primary drug resistance was 15% in 1991, 
while acquired drug resistance was 60%. In 2000 these parameters of drug 
resistance increased to 33% and 85%, respectively (unpublished data from 
the Arkhangelsk Regional Tuberculosis Dispensary (ARTD)). 
 
MDR 
MDR is defined as in vitro resistance of M. tuberculosis strains to two 
or more anti-tuberculosis drugs. MDR state in mycobacteriology refers to 
simultaneous resistance to at least R and H (with or without resistance to 
other drugs). Multi-drug resistant TB causes most concern because mortality 
is significantly higher among persons infected with multi-drug resistant strain 
than of those infected with sensitive strain. Second or third line drugs are 
necessary for treatment and they have greater side effects. Patients with 
multi-drug resistant TB remain infectious for longer time that increases the risk 
of infection transmission.35,38,39 
The emergence of multi-drug resitant TB overlapped with the 
resurgence of TB. Nosocomial outbreaks of multi-drug resistant TB have been 
reported in the USA, France and other countries.13,27,40 These outbreaks 
occurred in hospitals, nursing homes, shelters for the homeless, residential 
facilities for patients with HIV infection and acquired immune deficiency 
syndrome (AIDS) and correctional institutions.41 
Clinical manifestation of multi-drug resistant TB has many features that 
have been described among patients with HIV infection and TB. The manifes-
tation is characterised by fever, cough, dyspnea and night sweats.40 
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Outcomes of multi-drug resistant TB is usually poor with high mortality 
rate. Persons with multi-drug resistant TB were reported to have more likely 
alveolar infiltrates, cavity pulmonary lesions, reticular intersticial infiltrates, and 
respiratory insufficiency than those infected with susceptible strain.42 
Multi-drug resistant TB should be suspected in the following cases:  
• Patients in hospitals or prisons known to be experiencing outbreaks of 
multi-drug resistant TB; 
• Patients from geographic areas where multi-drug resistant TB is common;  
• Patients known to be at high risk for multi-drug resistant TB, those infected 
with HIV and having AIDS, intravenous drug users or homeless;  
• Patients who have relapsed after prior treatment.43 
 
Molecular mechanisms of drug resistance development 
M. tuberculosis is naturally resistant to many antibiotics particularly 
those belonging to the β-lactam, macrolide or tetracycline families. This is a 
result of its highly lipophilic cell envelope acting as an efficient barrier.19,31 
According to the recent advances of molecular biological technics, 
some of the genetic mechanisms of drug resistance has been uncovered. The 
mechanisms are chromosomal, caused by one or more mutations in 
independent genes. Drug-resistant organisms are produced by random 
mutations occurred spontaneously at different gene loci at a low but 
predictable frequency in wild type (WT) strains even before the strains come 
in contact with anti-tuberculosis drugs. These gene mutations occur at fairly 
consistent rates – approximately 10-6 for H and S, 10-8 for R and 10-4 for E. 
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When two or more drugs are considered together the value becomes the 
product of the individual probabilities. The mutation rate for resistance to more 
than one drug is calculated by multiplying the rates for the individual drugs. 
For example, the mutation rate for resistance to both H and R is 
approximately 2.56∗10-10. The probability of MDR development is dependent 
on the number of mutant bacilli.34,44,45 
Wild mutations of M. tuberculosis are considered to be equally 
distributed in all parts of the world. A high primary resistance rate in a certain 
region results from an inefficient national TB control programme in the past, 
because of a huge transmission of drug-resistant strains in that region during 
the past years.38,46 
Mutations can produce bacilli resistant to any of the anti-tuberculosis 
drugs. The probability for resistance is very high for less effective anti-
tubercuosis drugs such as thiacetazone (Th), ethionamide (Eth), capreomycin 
(Capr), cycloserine (Cycl) and viomycin; intermediate for drugs such as H, S, 
E, kanamycin (K) and para-aminosalicylic acid (PAS); and the lowest for R. 
Consequently the probability of a mutation is directly proportional to the bacte-
rial load. Resistance to a drug does not confer any selective advantage to the 
bacterium unless it is exposed to that drug.38,47 
An untreated TB cavity has 107-1010 organisms, thousands of which are 
resistant to a single drug due to a random mutation. The chance of having an 
organism with WT resistance to two drugs is the product of individual 
probabilities. Drug-resistant TB occurs when drug-resistant bacilli outgrow 
drug susceptible bacilli. Drug-resistant mutants are selected when therapy is 
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inadequate and when a single drug is used to treat a large population of 
bacilli. If a cavitary lesion is treated with a single effective drug the susceptible 
bacilli are eliminated but the small number of mutants resistant to the drug 
continue to multiply. After 2 weeks to several months of treatment with the 
single drug, the susceptible bacilli will be eliminated but the resistant bacilli will 
survive and continue to multiply causing clinical drug resistance to the 
particular drug. If the single anti-tuberculosis therapy is replaced by another 
effective drug than the second drug will kill bacilli sensitive for the second drug 
but the small number of mutants resistant to the second drug will survive. As a 
result mutants resistant to two drugs are selected. The patient may eventually 
have bacilli resistant to two or more drugs. The patient will relapse with the 
disease that is completely resistant to that drugs.48 
Selection favoring the resistant mutants occurs during several cycles of 
killing (when drugs are taken) and regrowth (when drug taking stops). During 
each cycle the size of bacilli population regrows back with the subsequent in-
creased proportion of resistant bacilli. Four mechanisms favoring resistant 
mutant selection will be described bellow. The first two occur during phases of 
bacterial inhibition or killing, and the second two occur during subsequent re-
growth.48 
First mechanism is known as bacterial effects during initial killing. Any 
regimen containing H kills M. tuberculosis more rapidly than those with R (but 
without H) do at the start of treatment. This suggest that at the commence-
ment of an H/R regimen, H-resistant mutants are selected because they can 
only be killed by R, whereas sensitive bacilli can be killed by the more bacteri-
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cidal H. There would only be a short period for selection since early bacteri-
cidal activities are only different during the first two days of treatment, after 
which the rate of kill is similar in all regimens. The bactericidal population at 
the start of treatment is high and likely to contain mutants resistant to a single 
drug. This mechanism would produce resistance if poor compliance took the 
form of cycles in which the patient took the combined preparation for 2-3 days, 
followed by at least several days when no drugs were taken, to allow the bac-
terial population to return to the pre-treatment state of growth. Although rele-
vant early bactericidal activity data are incomplete; there would probably be a 
slower selection of mutants resistant to a drug with a high early bactericidal 
activity, other than H, in any drug combination.48 
The second mechanism is called monotherapy during sterilisation of 
special populations. A hypothesis to explain the high sterilising activities of R 
and pyrazinamide (Z) has assumed that there are special populations of semi-
dormant organisms selectively killed by R (because they show spurts of me-
tabolism) and by Z (when the bacilli are in a very acid environment). Resistant 
mutants should then survive better than sensitive organisms. If we consider a 
single uninterrupted phase of sterilisation, the chances of resistant mutants 
surviving will depend on their prevalence within the original special bacterial 
population in the lesions of the patient.48 
The third effect is sub-inhibitory drug concentrations during regrowth. 
Anti-tuberculosis drugs may be present at sub-inhibitory concentrations during 
periods of regrowth. It can not inhibit growth completely, but it slows the 
regrowth down. The slowing of growth applies to sensitive bacilli, but not to 
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those resistant to drug A. Mutants resistant to A are selected. Second drug B 
does not affect this selection since, this happens during a period of regrowth. 
Thus B can not prevent some regrowth and have an equal effect on sensitive 
organisms and mutants resistant to A. There must also be a similar selection 
of resistance to B if sub-inhibitory concentrations of B are present. This 
mechanism would be most effective for drugs that have a high therapeutic 
margin, particularly H, for a long half-life, because their sub-inhibitory 
concentrations would exist after those for other drugs.48 
The fourth mechanism is bacteriopausal effects during regrowth. If we 
consider the situation when treatment is prescribed only with H and R. After 
the first few doses the sensitive bacilli are fully loaded with H. If there is then a 
gap in drug taking, the sensitive bacilli remain inhibited for several days, since 
5-7 days is the maximal lag period following exposure to H. The lag period af-
ter exposure to R is much shorter. As a result of these differences in lag peri-
ods, H-resistant mutants would be selectively encouraged at the time of re-
growth; they would not be inhibited by R because of its short lag period. This 
mechanism is likely to be most active in selecting mutants resistant to H and S 
since these two drugs have the longest lag period.48 
It is difficult to know which of these four mechanisms is most effective 
in producing resistant bacilli because of their complexity. The second mecha-
nism (monotherapy during sterilisation) would only produce resistance at re-
lapse and select for monoresistance to R. The other three mechanisms would 
mainly select for resistance to H initially, but could go on to cause resistance 
to other drugs being given. All mechanisms would operate irrespective of the 
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number of drugs being taken, provided that there were repeated cycles of kill-
ing and regrowth.48 
Treatment by single drug and changes of therapy regimens create 
possibility for development of resistance for several drugs. In a large 
population of resistant mutants, additional mutations can occur resulting in 
doubly resistant mutants. Patients acquire resistance to several drugs through 
repetition of the mutation process. Serial selection of drug resistance is the 
predominant mechanism for the development of MDR. The patients with MDR 
constitute a pool of chronic infections, which propagate primary MDR. 
Delayed recognition of drug resistance is one of the major factors contributing 
to multi-drug resistant TB development. These results in prolonged exposure 
to drugs that are virtually ineffective, creates possibility for resistant 
microorganism to multiply and prolonged infectiousness.41,48 
Similar situation occurs when the regimen contains multiple drugs but 
only one drug to which the infecting bacilli are susceptible. This can happen 
when primary drug resistance is not suspected or when a single drug is added 
to a failing regimen. These regimens are equivalent to single drug therapy, 
and they can select multi-drug resistant organisms. Bacilli may also be ex-
posed to a single drug for long periods of time when medications are not 
taken as prescribed, that allows drug-resistant organisms to emerge. 
When the treatment regimen contains two effective bactericidal drugs 
each drug eliminates the subpopulation of organisms with WT resistance to 
the other drug. But the possibility for resistant bacilli to survive exists. Effective 
cure can be provided by regimens containing at least two drugs to which M. 
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tuberculosis strain is sensitive. This statement was proved by contolled trials. 
They demonstrated that combined regimens were more efficient than single 
drug regimens in treating TB and preventing the emergence of drug resis-
tance.34,49 
Anti-tuberculosis drugs have individual targets in M. tuberculosis re-
sponsible for the resistance development. R has a single target in 69 bp po-
lymorphic fragment of the gene encoding for the β-subunit of the ribonucleic 
acid (RNA) polymerase (rpoB) responsible for its resistance. Two possible 
mechanisms of R resistance are mutations of RNA polymerase and altera-
tions in cell wall permeability that inhibit drug uptake.42 The RNA synthesis is 
inhibited in bacteria by R bonding to the deoxyribonucleic acid (DNA) depend-
ent RNA polymerase. 
Other anti-tuberculosis drugs have more complicated mechanisms as 
they may have several targets responsible for drug resistance. Mutations in 
katG and inhA genes cause resistance to H. KatG gene encodes the haem-
containing enzyme, catalase-peroxidase. There are biochemical and genetic 
proofs that H undergoes a peroxidative reaction catalysed by catalase-
peroxidase, in which it is transformed into an exquisitely potent bactericidal 
derivative. The precise nature of this compound remains obscure. It has been 
proposed that H may be converted into isonicotinic acid, an analogue of nico-
tinic acid the precursor for nicotinamideadenine dinucleotide (NAD) synthesis. 
It remains unclear whether catalase-peroxidase directly transports H into the 
cell or acts indirectly by maintaining the membrane transport system. Muta-
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tions in katG may affect enzyme levels and thus may be responsible for vary-
ing degrees of resistance to H.42 
InhA gene encodes an enzyme involved in mycolic acid production. 
Most isolates that contain inhA mutations in the absence of mutations in katG 
have relatively low level H resistance, less than or equal to 1 µg/ml, while iso-
lates with a complete deletion of katG can have minimum inhibitory concentra-
tions as high as 50 µg/ml.42,50 However, there may be another target confined 
to M. tuberculosis.  
The potential mechanisms of resistance to H include: 
• mutations that inhibit the suppression of the mycolitic acid synthesis 
pathway; 
• mutations in the biosynthesis pathway that would inhibit the assem-
bly of the catalase-peroxidase of M. tuberculosis to an active com-
pound; 
• inactivation of an inhibitor of NAD glycohydrolase, which depletes 
intracellular concentrations of NAD. 
Molecular basis for S resistance had been extensively studied on sev-
eral other eubacteria where it was known to result from mutations in genes for 
ribosomal subunits. S interferes with protein synthesis in mycobacteria by 
binding to the 16S ribosomal RNA causing misreading of the genetic code and 
inhibition of translation. Mutations in the 16S rRNA gene and gene strA – en-
coding for ribosomal protein s12 which stabilises a functionally important 
pseudoknot structure formed by 16S rRNA – confer resistance to S in M. tu-
berculosis.43,50 
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Initial reports described the E mechanism as binding to the cell wall. 
Later inhibition of arabinogalactan synthesis that is the component of the cell 
wall was presented at the most relevant function. Genetic explanation of E re-
sistance is mutation in embCAB gene cluster.50 More recently the inhibition of 
glucose conversion into the precursors used for the synthesis of cell wall poly-
saccharides such as arabinogalactan, arabinomannan and peptidoglycan has 
been proposed. A non-contiguous genomic region has been cloned and pre-
sented in a preliminary report as containing determinants, which encode the 
putative target of E. 
 
Risk factors for the development of drug resistance 
A limited number of studies has been performed to estimate the 
problem of drug resistance and determine risk factors for its development in 
Russia. We would like to distinguish and discuss separate risk factors for the 
development of acquired or resistance among previously treated cases and 
primary or drug resistance among new cases. 
 
Risk factors for the development of resistance among previously treated 
cases 
Previous treatment for TB, non-compliance to treatment or failure to 
complete a curative course of therapy and inadequate management by a 
physician during the treatment for TB are considered to be risk factors for the 
development of acquired drug resistance or resistance among previously 
treated cases. 
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Previous treatment for TB is considered by many authors to be either 
important cause or risk factor for the development of drug resis-
tance.25,34,38,42,45 The success of the drug treatment of TB has been the cata-
lyst for the emergence of drug resistance. Patients have been allowed to take 
their medications at home completely unsupervised. There is a danger that if 
the patient is sent home with three separate drugs, he or she might take a 
single drug at a time. In the patient with extensive lung disease taking a single 
drug just a few days may allow drug resistance to emerge. If a patient hap-
pens to be resistant to one drug and takes a combination of two drugs includ-
ing the one to which he is resistant, drug resistance to the second drug will 
emerge. Similarly if the patient is resistant to two drugs, and takes these two 
drugs and a third only then resistance to the third will emerge and so on.51 
Patients with drug resistance often have a history of not taking the pre-
scribed anti-tuberculosis medications for at least 1 month or have not received 
the recommended retreatmen regiment. This allows bacilli to accumulate mu-
tations and acquire resistance.25 
Non-compliance due to patient's related reasons is the most important 
factor in the emergence of acquired resistance. The reasons for non-
compliance considered as patient's responsibility usually are multifaceted 
resulting from characteristics of the individual patients and quality of their 
social and economic background. Some potential barriers to successful 
treatment include the need for long term (6 to 12 months) and complicated 
drug regimens, the cost in time and money, long waits in crowded public 
health facilities, contradictory expectations and beliefs between patients and 
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health care providers, communication difficulties and transportation. Home-
lessness, psychiatric diseases, alcoholism, drug addiction and substance 
abuse can predict non-compliance. Persons who use alcohol and other drugs 
may be at risk for repeated exposure to those who have TB.34,38,45,52 
Poor compliance can also be caused by health system failure. Failure 
to complete a curative course of therapy can be due to improper prescribed 
treatment that is wrong choice of anti-tuberculosis drugs or prescription ther-
apy not according to the standard treatment for different case categories.25,34 
Inadequate therapy can be due to suboptimal dosages and reduced 
absorption of the drugs.43 Several reports suggest that malabsorbtion of anti-
tuberculosis drugs may favour the development of drug resistance. Alterations 
of pharmacokinetics can lead to subtherapeutic concentrations of anti-
tuberculosis and thereby promote the emergence of drug resistance within in-
dividual patients.38 
Many cases of drug-resistant TB arise from inadequate management 
by a physician or ineffective TB control programme. The most common errors 
are addition of a single drug to a failing regimen, inappropriate single drug 
therapy, an inadequate initial regimen, failure to recognise primary or acquired 
resistance and failure to recognise or deal with non-adherence to prescribed 
treatment.34 
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Risk factors for the development of resistance among new cases 
Contact with a person having infectious, drug-resistant TB, HIV 
infection and immunocompromised conditions other than HIV infection are the 
risk factors for the development of primary or resistance among new cases. 
Contact with a person, who has infectious, drug-resistant TB is a 
significant factor for primary resistance. Recent nosocominal outbreaks 
demonstrate a strong correlation between previous exposure to a patient who 
has infectious, multi-drug resistant TB and the subsequent development in the 
contact of multi-drug resistant TB. Several factors are important and they 
should be taken into consideration in risk assessment. They are the 
infectiousness of the possible source; the closeness and intensity of the 
exposure and the contact’s likelihood of exposure to persons with drug 
susceptible TB. Any person who shares the air space with a patient with multi-
drug resistant TB for a relatively prolonged time (e.g., household member, 
hospital roommate) is at higher risk for infection than those with a brief 
exposure to a multi-drug resistant TB patient, such as a one-time hospital 
visitor. Exposure of any length in a small, enclosed, poorly ventilated area is 
more likely to result in transmission than exposure in a large, well-ventilated 
space. Exposure during cough inducing procedures (e.g., bronchoscopy, 
endotracheal intubation, sputum induction, and administration of aerosol 
therapy) may greatly enhance TB transmission is also more likely to result in 
infection.12 
HIV infection is another risk factor for the development of primary drug 
resistance.42,43,53 One of the most alarming consequences of dual infection 
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with HIV and M. tuberculosis has been the emergence of MDR. A 
transmission of multi-drug resistant TB among individuals in contact tended to 
occur very quickly. These included patients, prison guards and health care 
workers. Persons with HIV infection are more likely to be infected with TB if 
exposed. A type of catastrophic spread of these multi-drug resistant TB 
infections in nosocominal or closely similar congregational settings might thus 
occur. The HIV epidemic may have a significant effect on the spread of pri-
mary drug resistance in communities with co-existent HIV and drug-resistant 
TB since contacts of HIV infected people with M. tuberculosis are more likely 
to result in active disease and more quickly compared with contacts of 
infected immunocompetent people. This explains the high level of primary 
drug-resistant TB when combination of TB, inadequate treatment and HIV 
infection is observed.25,31,38 
The diagnosis of TB in HIV infected persons is sometimes delayed 
because of the unusual radiographic presentations of TB, co-infection with 
other pulmonary pathogens to which patients’ symptoms were attributed, and 
the overgrowth of M. tuberculosis in the laboratory by other mycobacteria. 
Delays in diagnosis lead to delays in the initiation of isolation and treatment 
and prolonged infectiousness. Prolonged infectiousness promotes further 
transmission. 
A high risk for developing multi-drug resistant TB includes immuno-
compromised conditions other than HIV infection. They include conditions re-
quiring prolonged high dose corticosteroid therapy and other immunosupres-
sive therapy including bone marrow and organ transplantation, chronic renal 
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failure, some haematological disorders e.g., leukemia and lymphoma, sys-
temic diseases of connective tissues, and acquired immunodefficiency condi-
tion other than HIV infection. 
 
Restriction fragment length polymorphism (RFLP) analysis in mycobac-
teriology 
In the past few years there has been a large increase in the application 
of molecular techniques to various aspects of mycobacteriology. The discov-
ery of insertion elements in mycobacterial species has made it possible to dif-
ferentiate strains for either epidemiological studies or to determine sources of 
mycobacterial contamination that could lead to false diagnosis of the disease. 
Chromosomal DNA is first digested, electrophoretically separated and then 
transferred to a membrane for hybridisation with labelled genetic probes de-
signed to detect copies of the insertion element. The tracking of patient to pa-
tient transmission of M. tuberculosis is of highest concern. Standardised 
methods for the detection of copies of insertion element IS6110 have been 
internationally accepted for typing M. tuberculosis.54 
RFLP has proved to be accurate in the determination of M. tuberculosis 
strain relatedness and in the recognition of distinct outbreaks. Systematic 
DNA fingerprinting of M. tuberculosis isolates proved to be a powerful tool for 
the study of interstrain relations in community. RFLP analysis with the inser-
tion sequence IS6110 is useful for the characterisation of M. tuberculosis 
strains, the identification of outbreaks and for tracing of nosocomial infec-
tions.55-57 
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Comparison of resistant and susceptible M. tuberculosis strains using 
RFLP analysis has been performed in several studies. Some researchers tried 
to identify whether certain risk factors for TB were associated with specific 
RFLP types. For example, injection drug users, alcoholism, pulmonary infec-
tion as the major site of the disease and homelessness were significantly as-
sociated with having a shared DNA fingerprint. Significant association was not 
found between DNA fingerprint clustering and race, sex, HIV status or non-
intravenous drug use.58 
 
The Arkhangelsk study 
The Arkhangelsk oblast is situated in the North of the European part of 
Russia and covers a territory of 589.900 sq. km. The administrative 
organisation of the oblast is composed of 20 districts (raions), 13 towns, 38 
settlements of urban type, about 4.000 rural settlements. The population of 
the oblast is 1.493.000 inhabitants (according to the estimation made by the 
end of 1998), with a density of 2.5 inhabitants per sq. km. The urban 
population is 1.086.500 and the rural population is 373.400 inhabitants. The 
major part of the population lives along railroads and in the basins of big rivers 
– Severnaya Dvina, Vaga, Pinega, Onega, and Mezen. In the economic 
system of Russia the Arkhangelsk oblast stands out as an area of timber, 
woodworking and pulp and paper industries, timber export and fish industry. 
Phthisiopulmonology service of the Arkhangelsk oblast was founded in 
1923. It was presented by hospitals and departments for TB treatment situ-
ated in every raion of the oblast. After the Second World War service was 
  
 
44
centralised. ARTD started to play the key role in TB control. The hospital in 
Majmaksa (Arkhangelsk) was opened in 1962. It provided treatment mainly for 
chronic patients. Small TB hospitals in the oblast were closed at the end of 
1960s. An inpatient department in the ARTD was opened in 1986. 
Nowadays TB service of the oblast is presented by the ARTD, Ma-
jmaksa hospital, 50 beds ward in Kotlas, 25 beds ward in Velsk, dispensary in 
Severodvinsk, sanatorium in Shenkursk and TB department in Regional Psy-
chiatric Hospital. 
The ARTD receives TB patients from the whole oblast and the city. The 
ARTD is divided in outpatient and inpatient departments. Inpatient department 
occupies 3 floors, each with one ward with 60 beds in each ward. The capac-
ity is 180 patients. Some efforts are made to separate patients with multi-drug 
resistant TB. The outpatient department is divided in 2 parts. One that looks 
after the different 13 districts in the municipality of Arkhangelsk city. Ten doc-
tors work there. One doctor in principle takes care of one district. The second 
part of outpatient department takes care of all raions in the oblast. Three 
oblast doctors work there. The oblast doctors receive patients’ medical docu-
ments concerning patients (x-ray, bacteriological examination, medical record 
etc) for consultation. Oblast doctor has the responsibility for several raions. 
If any person living in Arkhangelsk city or oblast is considered by the 
primary health service to suffer from TB he is then referred to the district TB 
doctor in the ARTD. If examination supports the TB diagnosis, the patient is 
usually admitted to inpatient department of the ARTD for the intensive phase 
of treatment. The continuation phase of treatment can be given either in 
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inpatient or outpatient departments of the ARTD for patients from the city of 
Arkhangelsk. Patients treated at inpatient department stay during the whole 
course in the ARTD. Patients receiving treatment in continuation phase at 
outpatient department come to the ARTD to get drugs. These patients come 
daily with the exception of Saturdays and Sundays. Some patients (20%) get 
drugs for 10 days at a time (continuation phase of category I with EH), and 
some (20%) are day-patients staying for the whole day and getting food in ad-
dition to their drugs. Others stay at home and are taken care by the nurse in 
the district, but the district TB specialist will also make home visits. The con-
tinuation phase of treatment for patients from the oblast can be given either in 
inpatient or outpatient department of the ARTD or in certain districts where the 
staff has been trained in the new TB strategy. Some patients can be referred 
to Majmaksa hospital for continuation phase. 
 
History of TB treatment in Arkhangelsk 
S and PAS were introduced in phthisiopulmonology practice in 
Arkhangelsk in 1940s, H, Cycl and Th – in 1960s and R – in 1973. The treat-
ment including H, S and PAS has been used since the end of 1960s. Doctors 
started to prescribe combination of H, R and S after introduction of R as anti-
tuberculosis agent. The treatment for TB usually included 3 drugs. Severely ill 
patients were given 4 drugs: H, R, S and E. Treatment was prescribed for 12 
months. After 3 months of treatment S was substituted by E. Treatment took 
place at inpatient department of the ARTD. After 6-8 months of treatment 
patients were discharged and continued treatment at outpatient department. 
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At this stage they received 2 anti-tuberculosis drugs: H and E or H and 
prothionamide (Pr). Individual treatment was started to be prescribed after 
introduction of R and E into practice. Prophylactic courses of chemotherapy 
with either H or other 2 anti-tuberculosis drugs were administered during 2 or 
3 months until 1998. 
In 1998, the implementation of treatment based on the Directly Ob-
served Treatment Shortcourse (DOTS) strategy was started. Nowadays 
treatment for TB is prescribed according to standard treatment regimens for 
different case categories (Table 2).59 Anti-tuberculosis drugs and dosages are 
presented in the Table 3.59 
In many cases the intensive phase of treatment is prolonged until re-
sults of susceptibility test are known. The results of sensitivity test are usually 
available after 10-12 weeks. Decisions are then made concerning further 
treatment according to the methodology recommendations.59 
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Table 2  Chemotherapy regimens for different case categories prescribed in 
the Arkhangelsk oblast59 
 
Category   TB patients                               Alternative treatment regimens 
                                                                
                                                           Initensive phase     Continuation phase
 
I                new case                               2EHRZ                4HR; 6HE; 4H3R3 
 
II               relapse, failure, default      2KEHRZ/1EHRZ     5HRE; 5H3R3E3 
 
 
III              new smear neg PTB,             2HRZ                  4HR; 6HE; 4H3R3 
                 (primary TB in children, 
                 extra-PTB without severe 
                 complications) 
 
IV              chronic case, MDR                 individual treatment regimens  
                                                                 according to results of suscepti- 
                                                                 bility tests 
 
TB = tuberculosis; E = ethambutol; H = isoniazid; R = rifampicin; Z = pyrazi-
namide; K = kanamycin; new smear neg PTB = new smear negative case of 
pulmonary tuberculosis; extra-PTB = extrapulmonary tuberculosis; MDR = 
multidrug resistance 
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Table 3  Essential anti-tuberculosis drugs and dosages prescribed in the Ark-
hangeslk oblast59 
 
Drug    Mode of action           Max         Recommended dose (mg/kg) 
                                              daily       
                                              dose             Daily              Intermittent 
                                                                                  
                                                                                       3x/wk            2x/wk 
H           bactericidal            300 mg          5(5-10)        10(8-12)      15(13-17) 
R           bactericidal            600 mg        10(8-12)        10(8-12)        10(8-12) 
Z           bactericidal                2.5 g      25(20-30)      35(35-40)      50(40-60) 
S           bactericidal                1.0 g      15(12-18)      15(12-18)      15(12-18) 
E           bacteriostatic             1.6 g      15(15-20)      30(25-35)      45(40-50) 
Eth, Pr  bactericidal             750 mg     12(10-20)              -                    - 
Ofl         slight bactericidal   800 mg    12(7.5-15)              -                    - 
K, A       bactericidal                1.0 g     15(12-18)       15(12-18)      15(12-18)
Capr      bactericidal                1.0 g     15(12-18)       15(12-18)      15(12-18)
Cycl       bacteriostatic         750 mg           10-20               -                     - 
 
3x/wk = 3 times a week; 2x/wk = 2 times a week; H = isoniazid; R = rifampicin; 
Z = pyrazinamide; S = streptomycin; E = ethambutol; Eth = ethionamide; Pr = 
prothionamide; Ofl = ofloxacin; K = kanamycin; A = amikacin; Capr = capreo-
mycin; Cycl = cycloserine 
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OBJECTIVES OF THE STUDY 
Superior objective – to reveal risk factors for the development of drug-
resistant TB in the Arkhangelsk oblast, Russia. 
Specific objectives: 
1. To identify social, demographical and medical factors associated with the 
development of drug-resistant TB. 
2. To compare the resistant and susceptible M. tuberculosis strains circulat-
ing in the Arkhangelsk population using RFLP analysis. 
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CHAPTER II 
MATERIALS AND METHODS 
Patients and bacterial strains 
The study was performed in the Arkhangelsk oblast on patients with 
pulmonary TB diagnosed and treated in the ARTD. 
Population at risk was 1.493.000 inhabitants of the Arkhangelsk oblast 
(according to estimation made by the end of 1998). 
Target population consisted of TB patients from the Arkhangelsk 
oblast. 
Study sample included patients from the Arkhangelsk oblast with new 
and previously treated cases of pulmonary TB. Patients diagnosed in the 
ARTD were selected according to the inclusion criteria.  
 
Inclusion criteria: 
1. Patients with new cases of pulmonary TB from whom strains have been 
collected during a 3 month period (June, July and August) in 1998. 
2. Patients with new and previously treated cases of pulmonary TB from 
whom strains have been collected during the second half of 1999 and dur-
ing the first 3 months of 2000. 
3. The strains must have been collected from the patients before the pre-
scription of treatment with anti-tuberculosis drugs. 
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Sample size 
The sample size for the study was calculated according to the WHO 
and IUATLD recommendations for sample size calculation for a survey on the 
prevalence of anti-tuberculosis drug resistance.32 Sample size was calculated 
using the lowest prevalence of resistance estimated according to the results of 
susceptibility tests performed at the National Institute of Public Health (NIPH), 
Oslo, Norway, on strains collected in the Arkhangelsk oblast.60 The lowest rate 
of drug resistance was observed for R. Estimated prevalence for R resistance 
was p=0.09. a=0.05 was chosen as allowable error. Number of observations 
was calculated as N= 4p(1-p)/a2 = 4×0.09×(1-0.09)/0.052 = 131. The sample 
size was increased by 15% to account for unexpected losses. The final sam-
ple size consisted of 150 M. tuberculosis strains. 
 
Collected sample 
A total of 146 M. tuberculosis strains isolated from patients with 
pulmonary TB in the ARTD during 1998–2000 were cultivated on Lowenstein-
Jensen media and forwarded to the NIPH, Reference Laboratory for Tubercu-
losis, for further analysis. Thirteen strains were either heavily contaminated or 
died during transportation. Among the remaining 133 strains, one strain (the 
first one isolated) per patient was selected. Then, the final sample consisted 
of 119 M. tuberculosis strains: 43 strains from 1998; 46 strains from 1999; and 
30 strains from 2000. 
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Representativeness of the sample 
Any person living in the Arkhangelsk oblast suspected to have TB by a 
general practitioner were routinely referred to the ARTD. Referral criteria in-
cluded suspicion of TB and did not depend on severity of the disease or pos-
sible development of drug resistance. The ARTD performed registration of pa-
tients and treatment. Selection of the sample did not exclude any patients with 
TB from other hospitals as registration and TB treatment was exclusively per-
formed in the ARTD. 
Private practice existed at a limited degree. There were only few pri-
vate doctors in Arkhangelsk. They were employed by state hospitals and had 
private practice as extra time work. Private doctors did not have responsibility 
to diagnose and treat TB. If a private doctor suspected TB in any patient then 
the patient was referred to the ARTD. 
According to the system described above all patients with TB in the 
Arkhangelsk oblast had an equal access to the ARTD and possibility to be in-
cluded in the study sample. The study sample included 57 of the 119 (47.9%) 
patients representing the city of Arkhangelsk and surrounding areas. The rest 
62 of the 119 (52.1%) patients represented all 20 raions of the oblast (Table 
4).
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Table 4  Patients representing the city of Arkhangelsk with surrounding areas 
and raions of the oblast 
Area                                                                            No of patients (%) 
The city of Arkhangelsk and surrounding areas                   57 (47.9) 
            Isakogorskyi raion                                                     3 (2.5) 
            Lomonosovskyi raion                                                16 (13.6) 
            Oktyabrskyi raion                                                      9 (7.6) 
            Solombalskyi raion                                                   10 (8.5) 
            Novodvinsk                                                               6 (5.1) 
            Primorskyi raion                                                        10 (8.5) 
            Tsyglomen                                                                2 (1.7) 
            Non                                                                           1 (0.8) 
Arkhangelsk oblast                                                               62 (52.1) 
            Cholmogorskyi raion                                                 4 (3.4) 
            Kargopolskyi raion                                                    4 (3.4) 
            Konoshskyi raion                                                      2 (1.7) 
            Kotlaskyi raion                                                          2 (1.7) 
            Krasnoborskyi raion                                                 1 (0.8) 
            Lenskyi raion                                                            1 (0.8) 
            Leshukonskyi raion                                                  3 (2.5) 
            Mezenskyi raion                                                       4 (3.4) 
            Nyandomskyi raion                                                  5 (4.2) 
            Onezskyi raion                                                         8 (6.8) 
            Pinezskyi raion                                                         5 (4.2) 
            Plesetskyi raion                                                        8 (6.8) 
            Shenkurskyi raion                                                     4 (3.4) 
            Ustyanskyi raion                                                       8 (6.8) 
            Verchne-Toemskyi                                                   1 (0.8) 
            Vinogradovskyi raion                                                2 (1.7) 
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The sample size was collected during fixed period of time as it is de-
scribed in the inclusion criteria. The analysis of quarterly reports on registra-
tion for the past 2 years allowed to conclude that there was no seasonal varia-
tions of TB diagnosis in the Arkhangelsk oblast. However a sharp increase of 
TB patients occurred in the III quarter of 1999. This was due to the change in 
the registration system. Since that time patients with TB diagnosed in the 
prison system of the Arkhangelsk oblast have been included in the reports. 
Individual analysis of data collection forms (Appendix) and records in 
the laboratory of the ARTD allowed to conclude that strains were collected 
from all new and previously treated patients during the 3 month period in 
1998. The rest strains were collected during the second half of 1999 and the 
first 3 months of 2000 on the first grow basis. Strains were collected from cul-
ture positive cases of pulmonary TB. Collection of sputum for culture examina-
tion was performed routinely from every patient at the point of diagnosis. The 
strains were collected from patients with pulmonary TB who have been regis-
tered in the quarter III and IV in 1999. Patients from the prison system were 
not included in the sample. During that period 148 patients were notified. 
Summary of the quarterly reports on registration for the III and IV quarter in 
1999 and characteristics of patients from whom the strains were collected are 
presented in the Table 5. 
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Table 5  Characteristics of patients with pulmonary TB registered in the III and 
IV quarter in 1999 in the ARTD and characteristics of patients with pulmonary 
TB whose strains were collected for the study 
The Arkhangelsk oblast               Strains collected               Total sample 
(excluding the prison system)     in the III, IV quarter             n = 119 (%) 
           n = 148 (%)                           n = 76 (%) 
                      
      new          treated                   new           treated            new       treated 
 
 111(75.0)     37(25.0)                54(71.1)     22(28.9)        89(74.8)   30(25.2) 
 
Data collection 
Medical records of the 119 patients were reviewed, retrospectively, in 
order to identify factors associated with the development of drug resistance. 
Demographic factors such as age and gender; social factors including smok-
ing habit, alcohol abuse and having been in prison; and medical factors such 
as presence of diabetes, gastric ulcer and chronic obstructive pulmonary dis-
ease (COPD) prior to TB diagnosis, possible contacts with another patients 
suffering from TB, and information about present treatment for TB were ana-
lysed. 
 
Strain susceptibility testing 
Susceptibility test to anti-tuberculosis drugs: H, R, E and S – was per-
formed by the radiometric broth method (BACTEC, Becton Dickinson Diag-
nostic Systems, Towson, MD)61-63 
The BACTEC method is a modification of the conventional proportion 
method. Instead of an agar base the test uses Middlebrook 7H12 broth with a 
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radiolabeled fatty acid substrate. Growth of M. tuberculosis in the medium re-
leases 14CO2 in the bottle that is measured radiometrically. The amount of 
growth, indicated by changes in the growth index (∆GI) in the medium with 
known drug concentrations as compared to that in the control bottle, has been 
correlated to a presence or absence of resistance in 1% of the inoculum. If an 
isolate grows beyond a specific growth index compared with the control it is 
considered resistant to that specific agent.63-65 
The concentrations of the anti-tuberculosis drugs used for the test were 
as follows: H, 0.2 µg/ml; R, 2.0 µg/ml; E, 7.5 µg/ml; and S, 6.0 µg/ml. 
In order to identify the mutations in the rpoB gene associated with R 
resistance, the Inno-Lipa Rif. TB Assay (Innogenetics N.V., Belgium) was per-
formed for every strain of M. tuberculosis resistant to R by the BACTEC 
method, following the instructions of the manufacturer.36,66 
Target DNA was amplified with the reagents of the kit. The downstream 
primer was biotinylated at the 5’ end. Polymerase chain reaction (PCR) ampli-
fication consisted of an initial denaturation at 95°C for 5 min, 30 cycles of de-
naturation at 95°C for 1 min, annealing at 55°C for 1 min and extension at 
72°C for 1 min, and terminal elongation at 72°C for 10 min. Amplified bioti-
nylated DNA material was hybridised with specific oligonucleotide probes im-
mobilised as parallel lines on membrane-based strips which was carried out 
by incubation in a shaking water bath at 62°C for 30 min. Streptavidin labeled 
with alkaline phosphatase was added to detect any biotinylated hybrid previ-
ously formed. Incubation with bromochloroindolylphosphate and nitro blue 
tetrazolium in dimethylformamide (BCIP/NBT) chromogen resulted in a pur-
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ple/brown precipitate. The presence of M. tuberculosis complex in the sample 
was monitored by the M. tuberculosis complex specific probe. The reactivity of 
an amplified fragment with the WT probes S1, S2, S3, S4 and S5 allowed an 
easy detection of the mutations that lead to R resistance in M. tuberculo-
sis.36,66 
 
RFLP analysis 
RFLP analysis (extraction of DNA, as well as the subsequent Southern 
blotting, hybridisation and detection) was performed according to standardised 
methodology.67-69 Briefly, cells were harvested by centrifugation and lysed 
with lysozyme and sodium dodecyl sulfate and genomic DNA was isolated by 
using CTAB (cetyltrimethylammonium bromide). DNA was restricted with 
PvuII (Boehringer Mannheim, Germany) according to the manufacturer’s 
instructions and electrophoresed in 0.8% agarose gel. After staining with 
ethidium bromide, the DNA fragments in the gel were photographed, and then 
transferred to a GeneScreen Plus membrane by the alkaline transfer 
procedure. The membrane was hybridised with DIG-labeled probe IS6110.68,69 
The results of hybridisation were inspected visually, scanned and compared 
by Gel Compar software version 4.1 (Applied Maths, Kourkai, Belgium) by the 
unweighted pair – group method of arithmetic averaging with the Dice coeffi-
cient. 
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Statistical analysis 
Epi Info version 6.04b (Centers for Disease Control and Prevention, 
USA; WHO, Geneva, Switzerland) was used for the main statistical analysis. 
Associations between categorical variables were assessed by the χ2 test and 
Fisher’s exact test for values less than five. Differences between groups were 
expressed as odds ratio (OR) with 95% confidence intervals (95% CI). Stu-
dent’s t-test was used to test for differences in means of continuous variables. 
A P value of < 0.05 was chosen as the level of significance. 
 
Definitions 
Cases were defined as patients with new and previously treated pulmonary 
TB whose M. tuberculosis strains were resistant to at least one drug. 
Controls were defined as patients new and previously treated pulmonary TB 
whose M. tuberculosis strains were susceptible. 
Pulmonary cases of TB included both sputum smear positive and sputum 
smear negative cases.70 
New cases were patients who have never previously been treated for TB for 
more than 1 month.70 
Previously treated cases were patients with a history of previous treatment 
with anti-tuberculosis drugs for at least 1 month.32 
Resistance to the first line anti-tuberculosis drugs (H, R, E, S) was defined ac-
cording to the results of susceptibility test by the BACTEC method. 
Any kind of resistance was defined as resistance to at least one anti-
tuberculosis drug. 
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MDR was defined as resistance to at least H and R.32 
Drug resistance among new cases (formerly: “primary drug resistance”) was a 
resistance of M. tuberculosis strains isolated from newly diagnosed patient 
who has never received anti-tuberculosis drugs or has received them for less 
than 1 month.22 
Drug resistance among previously treated cases (formerly: “acquired drug re-
sistance”) was a resistance of M. tuberculosis strains isolated from previously 
treated patients.22 
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CHAPTER III 
RESULTS 
Drug resistance of the M. tuberculosis strains 
A total of 119 strains collected from patients with pulmonary TB in the 
Arkhangelsk oblast were identified as M. tuberculosis and tested by the BAC-
TEC method for susceptibility to the first line anti-tuberculosis drugs: E, H, R 
and S. The susceptibility pattern to R, H, S and E of the 119 M. tuberculosis 
strains are represented in the Table 6. 
Fifty-two of the 119 (43.7%) strains were susceptible to all tested anti-
tuberculosis drugs. Monoresistance to S, H and E was detected in 8 (6.7%), 4 
(3.4%) and 4 (3.4%) strains, respectively. Resistance to two drugs was de-
tected in 17 of the 119 (14.3%) strains, to three drugs in 7 of the 119 (5.9%) 
strains, and to four drugs in 27 of the 119 (22.7%) strains. Thirty of the 119 
(25.2%) strains were multi-drug resistant. All strains resistant to R were multi-
drug resistant. 
Strains were collected from 89 (74.8%) newly diagnosed patients and 
from 30 (25.2%) previously treated patients. MDR among previously treated 
patients was four times higher than among new cases (Table 7). Resistance 
to at least one drug was found in 44 of the 89 (49.4%) strains collected from 
new cases and 23 of the 30 (76.7%) strains collected from previously treated 
cases. The highest rates of drug resistance were observed for S and H in both 
groups of strains: 40.4% and 66.7% of strains collected from new and previ-
ously treated patients were resistant to S, respectively; 37.1% and 73.3% of 
strains collected from new and previously treated patients were resistant to H, 
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respectively (Table 7). MDR existed at alarming rates. A total of 12 of the 89 
(13.5%) strains isolated from new cases were resistant to R and H, while 
MDR among strains from previously treated cases was 60.0%. All multi-drug 
resistant strains were also resistant to S and most of them also to E. 
 
Table 6  Susceptibility pattern of M. tuberculosis strains isolated from 119 pa-
tients with pulmonary TB in the Arkhangelsk oblast, Russia, 1998-2000, de-
termined using the BACTEC method 
 
    Rif      H      S      E      No new cases      No previously      Total cases 
                                          n = 89 (%)           treated cases     n = 119 (%) 
                                                                                    n = 30 (%) 
    R        R      R      R        11 (12.4)               16 (53.4)            27 (22.7) 
    R        R      R      S        1 (1.1)                    2 (6.7)               3 (2.5) 
    S        R      R      R        3 (3.4)                    1 (3.3)               4 (3.4) 
    S        R      R      S        13 (14.6)                1 (3.3)               14 (11.7) 
    S        R      S      S         2 (2.2)                   2 (6.7)               4 (3.4) 
    S        R      S      R         3 (3.4)                   0 (0)                  3 (2.5) 
    S        S      R      S         8 (8.9)                   0 (0)                  8 (6.7) 
    S        S      S      R         3 (3.4)                   1 (3.3)               4 (3.4) 
    S        S      S      S         45 (50.6)               7 (23.3)             52 (43.7) 
 
R = resistant; S = susceptible 
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Table 7  Resistance of M. tuberculosis strains isolated from 119 patients with 
pulmonary TB in the Arkhangelsk oblast, Russia, 1998-2000, to the first line 
anti-tuberculosis drugs, determined using the BACTEC method 
 
                                                      New case          Previously treated case 
                                                      n = 89 (%)                n = 30 (%) 
Resistance to ethambutol                20 (22.5)                  18 (60.0) 
Resistance to isoniazid                    33 (37.1)                  22 (73.3) 
Resistance to rifampicin                   12 (13.5)                  18 (60.0) 
Resistance to streptomycin              36 (40.4)                  20 (66.7) 
Resistance to any one drug             44 (49.4)                   23 (76.7) 
MDR                                                 12 (13.5)                   18 (60.0) 
 
MDR = multidrug resistance 
 
The 30 strains resistant to R with the BACTEC method were 
investigated by Inno-Lipa Rif. TB Assay to identify the mutations associated 
with R resistance in the Arkhangelsk oblast. Amplicons of the 69 bp polymor-
phic fragment of the rpoB gene obtained from these specimens were 
hybridised with Lipa to confirm resistance to R and detect the mutation in the 
core region of rpoB gene. Inno-Lipa Rif. TB Assay confirmed resistance to R 
of all 30 strains resistant by the BACTEC method. Seven different hybridisa-
tion patterns were represented (Table 8). Possible mutations in the rpoB gene 
of M. tuberculosis and corresponding Inno-Lipa patterns are represented in 
the Table 9. 
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The most common Inno-Lipa pattern was R5, that was revealed in 21 
of the 30 (70.0%) strains. Other types of Inno-Lipa patterns were ∆S1, ∆S4, 
R2, ∆S3 and ∆S5, that were found in 10.0%, 6.7%, 3.3%, 3.3% and 3.3%, re-
spectively. 
One strain produced a certain type of binding pattern. It showed resis-
tant R4a pattern and at the same time it had bands typical to the WT M. tuber-
culosis strain. 
 
Table 8 Inno–Lipa patterns of 30 M. tuberculosis strains resistant to R by the 
BACTEC method 
 
        Inno-Lipa pattern                                            n = 30 (%) 
                   R5                                                    21 (70.0) 
                  ∆S1                                                     3 (10.0) 
                  ∆S4                                                       2 (6.7) 
                  R2                                                         1 (3.3) 
                  ∆S3                                                       1 (3.3) 
                  ∆S5                                                       1 (3.3) 
                  WT/R4a                                                                         1 (3.3) 
 
WT = wild type 
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Table 9  Mutations in rpoB gene of M. tuberculosis and corresponding Inno-
Lipa patterns 
 
Mutated rpoB              rpoB mutation               Amino acid              Inno-Lipa 
      Codon                                                            change                   pattern 
None                                  none                             none                       WT 
513                              CAA → CTA                 Gln → Leu                   ∆S1 
516                             GAC → GTC                 Asp → Val                    R2 
516                             GAC → GGC                Asp → Gly                   ∆S2 
516                             GAC → TAC                 Asp → Tyr                WT/∆S2 
526                             CAC → TAC                  His → Tyr                     R4a 
526                             CAC → GAC                 His → Asp                    R4b 
526                             CAC → CTC                 His → Leu                   ∆S4 
531                             TCG → TTG                 Ser → Leu                    R5 
531                             TCG → TGG                Ser → Trp                    ∆S5 
533                             CTG → CCG                Leu → Pro                   ∆S3 
564                              CCT → CTT                Pro → Leu                  WT/R5 
 
C = cytosine; A = adenosine; G = guanosine; T = timine; Gln = glutamine; Leu 
= lecitine; Asp = asparagine; Val = valine; Tyr = tyrosine; His = histomine; Ser 
= serine; Trp = triptofan; Pro = proline; WT = wild type 
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RFLP analysis of the M. tuberculosis strains 
The 119 strains were analysed by the RFLP using IS6110 as a hybridi-
sation probe. The number of IS6110 copies varied between 7 and 17, with a 
mean number of 12.4 copies. Seventy RFLP patterns were revealed among 
119 strains, as shown on the Figure 1. Of the 70 RFLP patterns, 59 (84.3%) 
were unique and 11 (15.7%) were presented by 2–14 strains with identical 
RFLP pattern. These strains were clustered, meaning that each of them had a 
hybridisation pattern identical to at least one other strain. The largest epide-
miological cluster comprised 14 strains; other clusters included 11, 9, 8, 4 and 
2 strains. The five largest clusters included both R-susceptible and R-resistant 
organisms. Within the same cluster M. tuberculosis strains had different sus-
ceptibility patterns and mutations in the rpoB gene responsible for resistance 
to R, as shown in the Table 10. 
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Table 10  Resistance pattern in relation to clusters among M. tuberculosis 
strains 
 
Cluster size        Resistance to           No. strains            Inno-Lipa pattern 
                          ___________ 
                          E    H    Rif   S                                                (No. strains) 
     14                 S    S     S    R                    6 
                          R    R    R    R                     4                     ∆S1 (3)    R5 (1) 
                          S    R    S    R                     2 
                          R    S    S    S                     1 
                          S    S    S    S                     1 
     11                 R    R    R    R                     9                     R5 (8)    ∆S5 (1) 
                          R    R    S    R                     1 
                          S    R    S    R                     1 
      9                  S    R    R    R                     3                      R5 (2)    R2 (1) 
                          R    R    R    R                     2                      R5 (2) 
                          S    R    S    R                     2 
                          S    S    S    S                     2 
     8                   R    R    R    R                    6                       R5 (6) 
                          S    R    S    R                    1 
                          S    S    S    S                    1 
     4                   S    S    S    S                    3 
                          S    R    S    R                    1 
Rif = rifampicin; E = ethambutol; H = isoniazid; S = streptomycin; R = resis-
tant; S = susceptible 
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Description of epidemiological clusters 
The eleven clusters are identified by the capital letters A through E in 
order of decreasing size. The summary and characteristics of the five largest 
epidemiological clusters based on the RFLP findings are represented in the 
Table 11. 
Cluster A comprised 14 strains (4 strains from 1998, 5 strains from 
1999 and 5 strains from 2000). Twelve of the 14 (85.7%) strains were col-
lected from newly diagnosed patients with pulmonary TB. The age of the pa-
tients varied from 19 to 41 years, with a mean age of 30.0 years. Half of the 
patients were male. Three of the 14 (21.4%) patients have been living in the 
Arkhangelsk oblast for less than 10 years. Two of the 14 (14.3%) patients had 
been in prison. M. tuberculosis strains collected from 13 of the 14 (92.9%) 
strains were resistant to at least one drug. Four of the 14 (28.6%) strains were 
multi-drug resistant. Inno-Lipa test showed that ∆S1 pattern was dominant, as 
it was represented in 3 of the 4 R-resistant strains. R5 was the Inno-Lipa pat-
tern of the last strain (Table 10). 
Cluster B comprised 11 strains (1 strain from 1998, 6 strains from 1999 
and 4 strains from 2000). Six of the 11 (54.5%) strains were collected from 
newly diagnosed patients. The age of the patients varied from 25 to 70 years, 
with a mean age of 41.1 years. Seven (63.6%) patients were male. One of the 
11 (9.1%) patients has been living in the Arkhangelsk oblast for less than 10 
years. Six patients lived in the city of Arkhangelsk itself and 5 patients were 
from elsewhere in the oblast. Two of the 11 (18.2%) patients had a history of 
having been in prison. All strains collected from the patients within the cluster 
B were resistant to at least one anti-tuberculosis drug. Nine of the 11 (81.8%) 
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strains were multi-drug resistant. R5 Inno-Lipa pattern was dominant, as it 
was observed in 8 of the 9 R-resistant strains. ∆S5 was the Inno-Lipa pattern 
(Table 10) of the remaining strain. 
Cluster C consisted of 9 strains (7 strains from 1998, 1 strain from 
1999 and 1 strain from 2000). Six of the 9 (66.7%) strains were collected from 
new patients with pulmonary TB. The age of the patients varied from 19 to 56 
years, with a mean age of 37.7 years. Eight (88.9%) patients were male. One 
of the 9 (11.1%) patients has been living in the Arkhangelsk oblast for less 
than 10 years. Six patients lived in the city of Arkhangelsk and 3 patients were 
from elsewhere in the oblast. Four of the 9 (44.4%) patients had been in 
prison. M. tuberculosis strains collected from 7 of the 9 (77.8%) strains were 
resistant to at least one drug. Five of the 9 (55.6%) strains were multi-drug 
resistant. R5 Inno-Lipa pattern was dominant, as it was found in 4 of the 5 R-
resistant strains. The other found pattern was R2 (Table 10). 
Cluster D comprised 8 strains (2 strains from 1998, 3 strains from 1999 
and 3 strains from 2000). Half of the strains were collected from new patients 
with pulmonary TB. The age of the patients varied from 21 to 72 years, with a 
mean age of 43.5 years. Six (75.0%) patients were male. All patients were 
born in the Arkhangelsk oblast. Two patients lived in the city of Arkhangelsk 
and 6 patients outside. One of the 8 (12.5%) patients had been in prison. M. 
tuberculosis strains collected from 7 of the 8 (87.5%) patients within the clus-
ter D were resistant to at least one drug. Six of the 8 (75.0%) strains were 
multi-drug resistant. All R-resistant strains had R5 Inno-Lipa pattern. 
Cluster E comprised 4 strains they all were from the year 1998. Three 
of the 4 strains (75.0%) were collected from newly diagnosed patients. The 
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age of the patients varied from 31 to 61 years, with a mean age of 43.3 years. 
All patients were male. They all have been living in life in different districts of 
the Arkhangelsk oblast during the whole their life. They all had an evidence of 
being in prison. Three of the 4 (75.0%) strains of cluster E were susceptible to 
all drugs. One strain (25.0%) was resistant to both H and S. 
Cluster F comprised 3 strains, they all were from the year 1998. Two of 
the 3 (66.7%) strains were collected from new patients. The age of the pa-
tients varied from 27 to 46 years, with a mean age of 36.3 years. Two of the 3 
patients were male. All patients have been living in the Arkhangelsk oblast 
during their whole life. One of the 3 (33.3%) patients had been in prison. One 
of the 3 (33.3%) collected strains was resistant to H, the other two strains 
were susceptible. 
Cluster G comprised 2 strains they all were from the year 1999. The 
strains were collected from new patients. The age of the patients was 40 and 
46 years. Both patients were male. They have been living in the Arkhangelsk 
oblast during their whole life. One of them had been in prison. One of the 2 
strains was resistant to S, the other was susceptible. 
Cluster H comprised 2 strains, both from the year 2000. One strain was 
collected from newly diagnosed patient, the other was collected from patient 
previously treated for TB. The age of the patients was 39 and 42 years. Both 
patients were male. They have been living in the Arkhangelsk oblast during 
their whole life and both had been in prison. One of the 2 strains was resistant 
to H, the other was susceptible. 
Cluster I comprised 2 strains, both isolated in 1998, from new cases. 
The age of the patients was 37 and 39 years. Both patients were male, both 
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have been living in the Arkhangelsk oblast during their whole life in flats situ-
ated in the same house. The M. tuberculosis strains collected from these pa-
tients were resistant to H and S. 
Cluster J comprised 2 strains (1 strain from 1999 and 1 strain from 
2000), collected from new patients 39 and 47 years old with pulmonary TB. 
Both patients were male. One patient had been living in the Arkhangelsk 
oblast for less than 10 years, one patient had been in prison. Both strains col-
lected from these patients were susceptible to all drugs. 
Cluster K comprised 2 strains, isolated in 1998, from new cases. The 
age of the patients was 45 and 68 years. One of the patients was male. Both 
patients have been living in the Arkhangelsk oblast during the whole life. One 
patient had been in prison. One of the 2 strains was resistant to S, the other 
was susceptible. 
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Table 11  Characteristics of the five largest epidemiological clusters 
                             Cluster A    Cluster B    Cluster C    Cluster D    Cluster E 
                             n=14 (%)     n=11 (%)     n=9 (%)      n=8 (%)      n=4 (%) 
No of IS6110                  14                16             16                17              15 
No of new cases   12(85.7)         6(54.5)      6(66.7)        4(50.0)       3(75.0) 
Mean age                    30.0              41.1         37.7             43.5           43.3 
Male                        7(50.0)         7(63.6)      8(88.9)        6(75.0)     4(100.0) 
< 10 years               3(21.4)           1(9.1)      1(11.1)             0(0)            0(0) 
Being in prison        2(14.3)         2(18.2)      4(44.4)        1(12.5)     4(100.0) 
Any resistance      13(92.9)     11(100.0)      7(77.8)        7(87.5)       3(75.0) 
MDR                       4(28.6)         9(81.8)      5(55.6)         6(75.0)           0(0) 
 
< 10 years = living in the Arkhangelsk oblast less than 10 years; any resis-
tance = resistance to at least one drug; MDR = multidrug resistance 
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Patients 
All patients presented with pulmonary TB and were HIV negative. The 
age of the patients varied from 16 to 80 years, with a mean age of 38.9 years. 
Eighty-nine of the 119 patients (74.8%) were male.  
Patients’ weight varied from 37.0 kg to 100.0 kg, with a mean weight of 
61.3 kg. Body mass index (BMI) was calculated to estimate type of body con-
stitution. BMI varied from 16.3 to 36.2, with a mean of 21.3. Forty-one of the 
119 (34.5%) patients were underweight, that is BMI less than 20.0. Seventy-
four of the 119 (62.2%) patients had normal weight, that is BMI between 20.0 
and 24.9. Two of the 119 (1.7%) patients were overweighed, that is BMI be-
tween 25.0 and 29.9. Two of the 119 (1.7%) patients were obese, that is BMI 
more than 30.0. 
Almost all patients were native born in the Arkhangelsk oblast. Only 6 
of the 119 (5.0%) patients have been living in the Arkhangelsk oblast for less 
than 10 years. 
Marital status was assessed in terms of legal status. A total of 58 of the 
119 (48.7%) patients were married, 49 (41.2%) were single, 7 (5.9%) were 
divorced and 5 (4.2%) were widowed (Figure 2). 
The level of education was estimated as the highest last grade attained 
(Figure 3). The majority of the patients, that is 113 of the 119 (95.0%) pa-
tients, had secondary education. Three of the 119 patients (2.5%) had higher 
education. Two of the 3 patients with higher education were medical doctors 
employed in the ARTD. The third patient with higher education was an advo-
cate employed in the prison of Arkhangelsk. Three of the 119 (2.5%) patients 
had only primary education, due to mental disability. 
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Unemployment was relatively common among patients with TB, as 56 
of the 119 (47.1%) were unemployed. Forty-six of the 119 (38.7%) patients 
were employed, 14 patients (11.8%) were retired and 3 patients (2.5%) were 
students (Figure 4). Five of the 46 (10.9%) employed patients were occupied 
in the health sector as doctors, nurses and nurse assistants. Twenty-nine of 
the 46 (63.0%) employed patients had physical work and 12 (26.1%) em-
ployed patients had mental work (Figure 5). 
Residence was classified as private flats, homes and hostels. Ninety of 
the 119 (75.6%) patients lived in flats, 22 of the 119 (18.5%) patients lived in 
houses, 5 of the 119 (4.2%) patients lived in hostels and 2 of the 119 (1.7%) 
patients were homeless. The number of rooms in private house, flat or apart-
ment in a hostel varied from 1 to 6, with a mean number of rooms of 2.3. The 
number of persons living together in the same house, flat or hostel apartment 
varied from 1 to 7, with a mean number of persons of 3.0. The number of per-
sons per room in a housing unit varied from 0.2 to 4.0, with a mean number of 
persons per room of 1.4. Crowded accommodation was determined as more 
than 2 persons per room in housing unit. Thirty of the 117 (25.6%) patients 
had crowded living conditions (2 patients were excluded, as they were home-
less). 
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Figure 2 Marital status of 119 patients with pulmonary TB 
Figure 3  Education of 119 patients with pulmonary TB 
 
Figure 4  Occupation of 119 patients with pulmonary TB 
Figure 5  Occupation of 46 employed patients with pulmonary 
TB 
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As shown on the Figure 6, habit of smoking and alcohol abuse was 
found in 92 of the 119 (77.3%) and 54 of the 119 (45.4%) patients, respec-
tively. None of the patients was addicted to drugs. Thirty-six of the 119 
(30.3%) patients had been in prison during 0.3-17.0 years, with a mean dura-
tion of 5.5 years, prior to the disease. A total of 23 of the 36 (63.9%) former 
prisoners have been in prison for less than 5 years.  
Contact with another patient with TB was determined as living in the 
same flat or house or working together. It was relevant for 43 of the 119 
(36.1%) patients (Figure 7). Eighteen of the 43 (41.9%) patients who have 
had contact with another TB patient had contact with sick relative (parent, 
child, spouse, brother or sister). Two patients had a contact with sick parent 
employed in the health sector of the Arkhangelsk oblast. Nine of the 43 
(20.9%) patients communicated with a sick neighbor. Eight of the 43 (18.6%) 
patients have had contact with another TB patient while they were in prison. 
Seven of the 43 (16.3%) patients had contact with TB patients at their place of 
work, as 2 of the 7 were employed in the prison of Arkhangelsk, the other 5 
were medical doctors, nurses and nurse assistants. One of the 43 (2.3%) pa-
tients indicated that the contact person with TB was a former prisoner. 
Some patients had an indication of having chronic disease prior to TB 
diagnosis. Twenty-seven of the 119 (22.7%) patients have had a history of 
COPD, that is bronchial asthma, pneumonia more than twice during life period 
or chronic bronchitis. Seven of the 119 (5.9%) patients have had diabetes and 
8 of the 119 (6.7%) patients have had gastric ulcer prior to TB diagnosis. 
A previous treatment for TB was defined as treatment with anti-
tuberculosis drugs documented in medical records of the ARTD, as all pa-
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tients in the Arkhangelsk oblast suspected to have TB are referred to the 
ARTD. Thirty of the 119 (25.2%) patients had an evidence of previous treat-
ment for TB. Detailed information about their treatment is presented on Figure 
8. Thirteen of the 30 (43.3%) previously treated patients had been treated for 
TB in prison. Two of the 30 (6.7%) previously treated patients had been 
treated irregularly due to drug supply problem. Six of the 30 (20.0%) previ-
ously treated patients were treated not according to the standard treatment 
regimens for different case categories. The diagnosis and treatment of these 
6 patients took place in prison during the 1987–1997. At that time the DOTS 
strategy was not yet implemented in the Arkhangelsk oblast. One of these pa-
tients received mono-therapy with H during 6 months in 1987, the others re-
ceived therapy with 2 anti-tuberculosis drugs (HE or SH or SZ) or 3 drugs 
(SHP or SHE). Similar information was not available for 9 previously treated 
patients. The treatment of these patients took place in prison and prescribed 
drugs were unknown. The results of previous treatment for TB were the fol-
lowing. Six of the 30 (20%) patients were cured, 14 patients (46.7%) had 
treatment failure and 10 patients (33.3%) interrupted previous treatment. In-
terruption of treatment can be caused by patient and system related reasons. 
In all 10 cases the previous treatment for TB was interrupted due to patients 
related reasons, as 5 patients did it due to alcohol intake, 4 patients inter-
rupted treatment according to their own decision and 1 patients ad side ef-
fects to anti-tuberculosis drugs. 
A total of 36 of the 119 (30.3%) patients interrupted actual treatment for 
TB. Interruption of treatment can be caused by patient and system related 
reasons. In all 36 cases the treatment was interrupted due to patients related 
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reasons (Figure 9). Patient could interrupt treatment because of side effects to 
anti-tuberculosis drugs, alcohol intake and his own motivation. Seventeen of 
the 36 (47.2%) patients interrupted treatment due to alcohol intake. Sixteen of 
the 36 (44.5%) patients interrupted treatment according to their own decision. 
Three of the 36 (8.3%) patients interrupted treatment because they had side 
effects to anti-tuberculosis drugs. 
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Figure 6  Social factors of 119 patients with pulmonary TB 
 
Figure 7  Contact with another TB patient of 43 patients with 
pulmonary TB 
Figure 8  Details of previous treatment of 30 patients with 
pulmonary TB 
Figure 9  Reasons for interrupted treatment of 36 patients 
with pulmonary TB 
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Factors associated with infection with drug-resistant and multi-drug re-
sistant strain of M. tuberculosis 
To identify factors associated with the development of drug resistance 
in the Arkhangelsk oblast demographical, social and medical factors collected 
from the medical records of the ARTD were studied in relation to susceptibility 
patterns of M. tuberculosis strains. 
The majority in both groups of patients infected with resistant and sus-
ceptible M. tuberculosis was males, while there were more female patients 
infected with resistant strain (34.3%) than infected with susceptible (13.5%) 
(Table 12). Female gender was significantly associated with infection with 
drug-resistant strain (P = 0.01). Female gender was also significantly associ-
ated with infection with multi-drug resistant strain (P = 0.03) (Table 13). 
Patients previously treated for TB were infected either with resistant or 
susceptible M. tuberculosis. A total of 23 of the 67 (34.3%) patients infected 
with drug-resistant strain had an evidence of previous treatment for TB. Seven 
of the 52 (13.5%) patients infected with susceptible strain were treated previ-
ously. Previous treatment significantly contributed to development of the dis-
ease with drug-resistant strain (P = 0.01) (Table 12). 
A total of 18 of the 30 (60.0%) patients infected with multi-drug resis-
tant strain had an evidence of previous treatment for TB. Twelve of the 89 
(13.5%) patients infected with non-multi-drug resistant strain were treated 
previously. Previous treatment was significantly associated with disease due 
to a multi-drug resistant strain (P < 0.001) (Table 13). 
A total of 27 of the 67 (40.3%) patients infected with drug-resistant 
strain of M. tuberculosis have interrupted treatment for TB, while only 9 of the 
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52 (17.3%) patients infected with drug-susceptible strain did the same. Inter-
ruption of treatment for TB was significantly associated with drug resistance 
(P = 0.01) (Table 12). 
A total of 15 of the 30 (50.0%) patients infected with multi-drug resis-
tant strain of M. tuberculosis have interrupted treatment for TB, while 21 of the 
89 (23.9%) patients infected with non-multi-drug resistant strain did the same. 
Interruption of treatment for TB was significantly associated with multi-drug 
resistance (P < 0.001) (Table 13). 
Patients infected with drug-resistant and susceptible strains did not 
have significant difference in having COPD and diabetes prior to TB diagno-
sis. While patients infected with susceptible M. tuberculosis were more likely 
to suffer from gastric ulcer prior to TB diagnosis than those infected with drug-
resistant strain (P = 0.01) (Table 12). 
For the 46 employed patients occupation was classified into work with 
physical and mental activity. Twenty-four of the 46 (52.1%) employed patients 
were infected with drug-resistant strain. The remaining 22 of the 46 (47.9%) 
employed patients were infected with susceptible strain. Eleven of the 24 
(45.8%) employed patients infected with resistant strain had a physical work. 
While 18 of the 22 (81.8%) employed patients infected with susceptible strain 
had a physical work. Patients having physical work were more likely to be in-
fected with susceptible M. tuberculosis (P = 0.01) (Table 12). Similar associa-
tion was observed between having physical work and being infected with non-
MDR strain (P = 0.02) (Table 13). Patients with mental work had no significant 
difference in relation to infection with drug-resistant or susceptible strain. 
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Patients employed in health sector were analysed separately. Five of 
the 46 employed patients (10.9%) were employed in the health sector of Ark-
hangelsk as doctors, nurses and nurse assistants. All these patients were in-
fected with drug-resistant M. tuberculosis. Three of the 5 patients were new 
and had MDR. Employment in the health sector of Arkhangelsk was signifi-
cantly associated with the development of drug resistance (P = 0.03). 
No significant difference was observed between patients infected with 
drug-resistant and susceptible M. tuberculosis strains in relation to age, BMI, 
marital status, level of education, crowded accommodation, unemployment, 
smoking habit, alcohol abuse and contact with another TB patient. Surpris-
ingly an evidence of being in prison was not associated with drug resistance 
(Table 12) and MDR (Table 13). 
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Table 12  Demographic and medical profile of 119 patients with pulmonary TB in selection to infection with resistant and suscepti-
ble M. tuberculosis 
Characteristics                Infection with drug-resistant         Infection with drug-susceptible           OR (95% CI)                  P 
                                                 strain n = 67 (%)                             strain n = 52 (%) 
Female                                       23 (34.3)                                          7 (13.5)                               3.4 (1.2 – 9.7)                0.01 
Unemployment                           31 (46.3)                                        25 (48.1)                                0.9 (0.4 –2.1)                0.84 
Smoking habit                            51 (76.1)                                        41 (78.8)                               0.9 (0.3 – 2.2)                 0.72 
Alcohol abuse                            28 (41.8)                                        26 (50.0)                               0.7 (0.3 – 1.6)                 0.37 
Contact with TB patient              29 (43.3)                                       14 (26.9)                               2.1 (0.9 – 4.9)                 0.07 
Evidence of being in prison        17 (25.4)                                       19 (36.5)                               0.6 (0.3 – 1.4)                 0.18 
COPD                                         17 (25.4)                                       10 (19.3)                               1.4 (0.5 – 3.8)                 0.43 
Gastric ulcer                                   1 (1.5)                                         7 (13.5)                               undetermined                  0.01 
Diabetes                                         5 (7.5)                                           2 (3.8)                               2.0 (0.3- 16.0)                 0.34 
Previous treatment for TB          23 (34.3)                                         7 (13.5)                               3.4 (1.2 – 9.7)                 0.01 
Interruption of treatment for TB  27 (40.3)                                         9 (17.3)                               3.2 (1.2 – 8.3)                 0.01 
OR = odds ratio; 95%CI = 95% confidence interval; TB = tuberculosis; COPD = chronic obstructive pulmonary disease 
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Table 13  Demographic and medical profile of 119 patients with pulmonary TB in selection to infection with MDR and non-MDR M. 
tuberculosis 
Characteristics                       Infection with MDR                   Infection with non-MDR               OR (95% CI)                   P 
                                                 strain n = 30 (%)                             strain n = 89 (%) 
Female                                         12 (40.0)                                       18 (20.2)                          2.6 (1.0 – 7.1)                 0.03 
Unemployment                             12 (40.0)                                       44 (49.4)                           0.7 (0.3 –1.7)                 0.37 
Smoking habit                              20 (66.7)                                       72 (80.9)                          0.5 (0.2 – 1.3)                 0.11 
Alcohol abuse                              12 (40.0)                                        42 (47.2)                         0.8 (0.3 – 1.9)                  0.49 
Contact with TB patient                14 (46.7)                                       29 (32.6)                         1.8 (0.7 – 4.6)                  0.16 
Evidence of being in prison            6 (20.0)                                       30 (33.7)                         0.5 (0.2 – 1.5)                  0.16 
COPD                                             6 (20.0)                                       21 (23.6)                         0.8 (0.3 – 2.5)                  0.68 
Gastric ulcer                                     1 (3.3)                                           7 (7.9)                         0.4 (0.1 – 3.6)                  0.35 
Diabetes                                         3 (10.0)                                           4 (4.5)                         2.4 (0.4- 13.8)                  0.24 
Previous treatment for TB            18 (60.0)                                        12 (13.5)                      9.6 (3.4 – 28.4)               <0.001 
Interruption of treatment for TB    15 (50.0)                                        21 (23.9)                        3.2 (1.2 – 8.4)               <0.001 
OR = odds ratio; 95%CI = 95% confidence interval; TB = tuberculosis; COPD = chronic obstructive pulmonary disease 
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CHAPTER IV 
DISCUSSION 
In the thesis we described the problem of resistance to anti-
tuberculosis drugs among new and previously treated patients, the molecular 
epidemiology of M. tuberculosis strains circulating in the Arkhangelsk oblast, 
Russia, and we identified community factors associated with the development 
of drug-resistant TB. 
 
The magnitude of M. tuberculosis drug resistance in the Arkhangelsk 
oblast 
The resurgence of TB in the Arkhangelsk oblast during the past 10 
years has been accompanied by high rates of drug resistance. Primary and 
acquired drug resistance in 1991 was 15% and 60%, respectively. In 2000, 
these parameters increased to 33% and 85%, respectively (unpublished data 
from the ARTD). 
Nowadays, TB and MDR are considered to be synonyms in Russia.9 At 
the same time the actual rates of drug resistance in Russia are not known, as 
there are no national statistics available.9,16 A major challenge nowadays is to 
monitor and control resistance to anti-tuberculosis drugs. A broad range of 
resistance rates has been reported by different oblasts, but overall drug-
resistant TB is common. According to surveys presented in the literature, pri-
mary and acquired MDR ranged from 4.0 to14.4% and from 19.2 to 54.4%, 
respectively.20 In the Ivanovo oblast, 5% of the strains collected from civilian 
patients with new cases of pulmonary TB during 1995-1996 were multi-drug 
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resistant.52 Resistance to at least one drug among new and previously treated 
patients were 29.0-32.4% and 57.8-68.5%, respectively.22 
Our study shows that resistance to at least one drug among new and 
previously treated cases was 49.4% and 76.7%, respectively. MDR among 
new and previously treated cases was found to be 13.5% and 60.0%, respec-
tively. Drug resistance rates in the Arkhangelsk oblast were thus higher than 
those described for different oblasts of Russia. 
In our study, monoresistance was found at very low rates for S, H and 
E. At the same time resistance to two, three and four drugs was observed 
more often. That is in agreement with another study from Russia.18 The fact 
that the highest rates of resistance in the Arkhangelsk oblast were observed 
for S and H was not surprising. As it was reported before, primary resistance 
to S and H was 40.0% and 25.0%, respectively,75 and parameters of acquired 
resistance were 84.0% and 82.0%, respectively. In our study, parameters of 
resistance among new cases are similar to those described before. The rates 
of resistance among previously treated cases have decreased. 
We did not observe monoresistance to R. Resistance to R predicted 
resistance to H and served as a marker of MDR. The fact that resistance to R 
is rarely observed without associated resistance to other drugs was confirmed 
by other studies.37,76 
 
Transmission of drug-resistant M. tuberculosis strains 
High rates of resistance to anti-tuberculosis drugs among new cases 
indicate that drug-resistant strains are circulated and transmitted from patient 
to patient in a high degree in the Arkhangelsk oblast. Transmission of already 
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resistant strains is a very important problem, as it impacts case management. 
TB control programme should have reliable laboratory facilities to diagnose 
drug resistance. The spread of multi-drug resistant strains raises the neces-
sity to implement rapid diagnostic methods for detection of resistance like 
Inno-Lipa. 
Active transmission of M. tuberculosis resistant strains in the commu-
nity can be measured. It is generally assumed that the proportion of clustered 
strains in a population reflects the amount of recent transmission.78 In our 
study, only 15.7% of M. tuberculosis strains were clustered. It was impossible 
to establish connections between all patients included in the same cluster. At 
the same time, it is evident that clustered cases belonged to the same chain 
of transmission directly or indirectly. The largest cluster in our material com-
prised 14 patients. Studies performed in Russia using RFLP analysis have 
revealed that the majority of clusters were small with 2 to 4 patients per clus-
ter.77,79 In the study conducted in the North-West part of Russia the maximum 
cluster size consisted of 10 patients.80 RFLP clusters contained 2, 3, 5 and 8 
strains in the studies performed in Asian countries on M. tuberculosis strains 
isolated from patients with pulmonary TB.81,82 The sample size of these stud-
ies were several times higher than ours. Although the proportion of strains in 
clusters was relatively low, a large size of RFLP clusters indicates existence 
of active transmission of M. tuberculosis strains in the Arkhangelsk oblast. 
M. tuberculosis strains included in the same RFLP cluster have differ-
ent mutations in the rpoB gene and, in addition, had resistance to various 
other drugs. This suggests active transmission of both drug-resistant and 
drug-susceptible strains of M. tuberculosis. 
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Mutations responsible for R resistance 
Our study shows that M. tuberculosis strains resistant to R have differ-
ent mutations in the rpoB gene. The fact that R5 pattern was the most com-
mon corresponds with previously published data.37,71-74,77 One strain was rep-
resented by two subpopulations of bacilli, one susceptible and one resistant to 
R. The mutation responsible for R resistance could have occurred during 
treatment, as the strain was isolated from patient previously treated for TB. 
The population of susceptible bacilli was not totally substituted by the popula-
tion of resistant bacilli at the time of strain isolation. Determination of mixtures 
of resistant and susceptible bacilli, especially mixture of WT M. tuberculosis 
strain and resistant having R4a pattern was described before.37,66 
 
Analysis of epidemiological clusters 
Patients with TB included in the epidemiological clusters presented the 
most economically productive age group, as their mean age varied from 30.0 
to 43.3. The majority of patients within the same cluster were males. The fact 
that a small proportion of patients (9.1%-21.4%) within the same epidemiol-
ogical cluster have moved to the Arkhangelsk oblast for less than 10 years 
ago indicates that migration in the Arkhangelsk oblast is low. TB epidemiol-
ogical situation there is not influenced by the process of migration. 
Every epidemiological cluster contained patients from the city of Ark-
hangelsk and from different parts of the oblast as well. Although it was practi-
cally impossible to establish all connections between patients included in the 
same cluster, it is likely that these patients belonged to the same chain of TB 
transmission, indicating the transmission is not limited in the city. 
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Risk factors for the development of drug-resistant TB 
Identification of factors associated with the development of drug resis-
tance is very important and helpful in planning anti-tuberculosis activities. A 
case control study conducted in the Ivanovo oblast, Russia, found that only 
homelessness was a risk factor for primary drug resistance.74 This factor was 
not relevant for the Arkhangelsk oblast, as only 2 patients of the total 119 
were homeless. In the Tomsk oblast, the major factor associated with MDR 
was higher socio-economic status, implying access to health services/anti-
tuberculosis medications and ongoing transmission, although these cases de-
nied prior use of anti-tuberculosis drugs.9 Access to health services and con-
tact with infectious TB cases was frequent for our 5 patients employed in the 
health sector. Three of these 5 patients were newly diagnosed and they were 
infected with multi-drug resistant M. tuberculosis. The fact that all these pa-
tients were infected with resistant strains deserves special attention. 
All patients included in our study were HIV negative. Increase of TB 
morbidity and mortality rates observed during the past 10 years in Russia was 
not associated with the HIV epidemic.20 
In the Arkhangelsk oblast, female gender was significantly associated 
with the development of drug resistance even though the majority of the pa-
tients were male. The same was described in Estonia, previous state of the 
Soviet Union.83 The opposite phenomenon is observed in United Kingdom 
where male gender is considered to be risk factor for drug-resistant TB. 
Certain social factors such as smoking habit, alcohol abuse and unem-
ployment were not associated with the development of drug resistance in the 
Arkhangelsk oblast, although found by others.52,83 
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The surprising factor that a history of being in prison in spite of a sig-
nificantly higher rates of drug resistance in the prison system of Russia was 
not associated with resistance to anti-tuberculosis drugs was also described 
in the Ivanovo oblast.52 Detailed analysis allowed to reveal that 21 of the 36 
patients who have had a history of being in prison (58.3%) were released from 
the prison during the 1970s and 1980s. While the epidemic of TB in the prison 
system of the Arkhangelsk oblast has been observed since 1994.21 Sixteen of 
the 36 previous prisoners (44.4%) have been treated for TB. The present ill-
ness of these patients could be due to reactivation of the infection (probably 
drug sensitive) that they have got while being in prison 20-30 years ago. At 
the same time these patients could be re-infected after the release from 
prison. In this case, they had a chance of being infected with either resistant 
or susceptible strain. It is generally believed that, if the prevalence of TB in the 
community is very low, TB is mainly caused by endogenous reactivation of 
primary infection.84 On the other hand, TB among people living in high TB en-
demic areas is assumed to be caused mainly by re-infection with M. tubercu-
losis.84 The risk of the disease development is influenced by the epidemiologi-
cal situation in the community. At the same time there is no clear evidence 
confirming that exogenous re-infection is the predominant cause of TB in high 
endemic countries.85,86 
A previous treatment for TB was defined as treatment with anti-
tuberculosis drugs documented in the medical records of the ARTD. Evidence 
of previous treatment for TB was significantly associated with the develop-
ment resistance to anti-tuberculosis drugs. This is in agreement with previ-
ously published data.25,34,42,45,87 
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Poor patient compliance is the most important reason for the develop-
ment of drug-resistant TB. Interruption of treatment for TB can be due to pa-
tient and system related reasons. Our study has shown that patient related 
reasons for non-compliance were common in the Arkhangelsk oblast. 
 
Future perspectives 
The results of present study can serve as a helpful tool for planning fur-
ther anti-tuberculosis activities in the Arkhangelsk oblast aimed to control the 
spread of drug-resistant TB. Treatment based on different case categories 
administered under direct supervision is very useful to prevent the develop-
ment of drug resistance during treatment. The implementation of treatment 
based on the DOTS strategy in the Arkhangelsk oblast was started in 1998. 
Medical staff was educated in new strategy. The treatment for TB is pre-
scribed according to different categories. Every case is discussed at the cen-
tral doctor’s commission at the time of diagnosis and end of intensive phase 
of treatment. Special attention is paid to the patients infected with drug-
resistant M. tuberculosis. Treatment of these cases is prescribed according to 
the individual susceptibility pattern, following the guidelines.59 All this is done 
in order to avoid mistakes in case management. Treatment of patients in-
fected with susceptible M. tuberculosis strains prescribed according to stan-
dard treatment regimens under direct supervision should led to cure. Admini-
stration of treatment to new patients infected with drug-resistant strains is 
problematic. Usually, 10-12 weeks will pass before the results of susceptibility 
test will be available. Treatment prescribed to a patient with a new case of 
pulmonary TB according to the category I can be equivalent of monotherapy if 
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a strain is resistant to 3 drugs. All these raises importance of diagnosis of 
drug resistance on time and importance of proper treatment regimen. 
Poor patient’s compliance is of great importance as interruption of 
treatment is the main reason for accumulation of mutations responsible for 
resistance to anti-tuberculosis drugs. Unfortunately, in Russia there is no law 
concerning TB treatment, in contrast to many countries of Western Europe 
where the law states that individual suffering from infectious TB creates risk 
for the health of other citizens and is obliged to be treated. Patients with poor 
compliance create conditions for the spread of M. tuberculosis in the commu-
nity, especially patients having a drug-resistant TB creates a severe risk for 
the health of many people. Infection with drug-resistant strain can result in 
more serious disease and necessity to prescribe second line drugs that are 
less effective and have more side effects. Our study has shown that non-
compliance in the Arkhangelsk oblast is due to patients related reasons. Es-
tablishment of a law on TB treatment with definition of patient’s and doctor’s 
responsibilities can help to solve the problem. 
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CONCLUSIONS AND RECOMMENDATIONS 
Conclusions 
1. Drug-resistant TB is an important problem in the Arkhangelsk oblast, Rus-
sia. 
2. Mono-resistance to anti-tuberculosis drugs is a rare phenomenon to ob-
serve. Simultaneous resistance to two or three drugs is common phe-
nomenon. 
3. MDR exists at an alarming level in the Arkhangelsk oblast. 
4. Resistance to R predicts resistance to H and can serve as a valid marker 
of MDR in the Arkhangelsk oblast. 
5. The highest rates of resistance are observed for S and H. 
6. Drug-resistant strains of M. tuberculosis are circulating in all raions of the 
Arkhangelsk oblast and they are transmitted at a high degree. 
7. The spread of drug-resistant TB is attributed to several risk factors: being 
female, evidence of previous or interrupted treatment for TB are the risk 
factors for the development of drug-resistant TB in the Arkhangelsk oblast. 
8. Employment in the health sector of Arkhangelsk was significantly associ-
ated with the development of drug resistance. 
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Recommendations 
1. It is important to monitor and control resistance to anti-tuberculosis drugs. 
2. The spread of drug-resistant TB raises the necessity to implement reliable 
laboratory facilities to diagnose drug resistance on time. Rapid methods of 
diagnosis of resistance to R, for example with Inno-Lipa, can serve as a 
helpful tool. 
3. Treatment of TB based on different case categories administered under 
direct supervision is useful to prevent non-compliance and development of 
drug resistance. 
4. TB control programme should use all efforts to ensure proper treatment of 
TB patients. Establishment of law on TB treatment can help to solve the 
problem. 
5. Special attention should be paid and preventive measures undertaken in 
order to control the development of TB with drug-resistant M. tuberculosis 
among medical personnel. 
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APPENDIX 
DATA COLLECTION FORM 
Patient information 
First name, family name___________________________________________ 
Culture number (ARTD)________________NIPH number________________ 
Date of registration_______________________________________________ 
Gender: ❏ male, ❏ female 
Date of birth____________________age_____________________________  
Weight_________kg  
Height _________cm 
BMI__________ 
Address (raion)_________________________________________________ 
Has been living in the Arkhangelsk oblast for________years 
Marital status: ❏ married, ❏ single, ❏ divorced, ❏ widowed 
 
Social information 
Education: ❏ primary, ❏ secondary, ❏ higher 
Occupation: ❏ student  
❏ employed: ❏ industrial worker, ❏ office staff, ❏ medical staff 
  ❏ unemployed 
  ❏ retired 
Housing: ❏ non, ❏ hostel, ❏ flat, ❏ house 
Number of rooms ____ number of persons living together _____ number of 
children under age of 15_____ number of persons per room______  
Smoking: ❏ no, ❏ yes 
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Narcotics abuse: ❏ no, ❏ yes 
Alcohol abuse: ❏ no, ❏ yes 
TB among relatives or other persons living together with the patient: 
❏ no, ❏ yes 
Being in prison: ❏ no, ❏ yes, for how many years_________, when_______ 
 
Medical information 
COPD: ❏ no, ❏ yes: ❏ bronchial asthma  
❏ pneumonia more than twice 
❏ chronic bronchitis 
Diabetes: ❏ no, ❏ yes 
Peptic ulcer: ❏ no, ❏ yes 
HIV status: ❏ negative 
  ❏ positive 
Case category: ❏ New case 
   ❏ Previously treated case 
 
For patients treated previously: 
Year when treatment took place____________________________________ 
Prescribed drugs during the previous treatment________________________ 
______________________________________________________________ 
Previous treatment took place in prison: ❏ yes, ❏ no 
Previous treatment was prescribed not according to the standard regiments 
for different case categories: ❏ no, ❏ yes 
Irregular drug supply during treatment: ❏ no, ❏ yes 
  
 
107
Results of treatment: ❏ cured, ❏ treatment completed, ❏ defaulted, ❏ failure, 
❏ relapse, ❏ chronic case, ❏ transferred out 
 
Laboratory data: 
1. Smear microscopy: date ________ ❏ positive, ❏ negative 
2. Culture date_________ 
 
Present treatment:  
Date of prescription______________________________________________ 
Prescribed drugs________________________________________________ 
______________________________________________________________ 
Alcohol intake during treatment: ❏ no, ❏ yes 
Interruption of present treatment: ❏ no, ❏ yes 
Reasons for interruption of present treatment: 
❏ system related (irregular drug supply) 
❏ patient’s related (❏ non-compliance with hospital rules, ❏ patient’s deci-
sion) 
Side effects of drugs: ❏ no, ❏ yes 
 
Microbiology data 
Results of susceptibility test (BACTEC) performed at the NIPH: 
E: ❏ susceptible, ❏ resistant 
H: ❏ susceptible, ❏ resistant 
R: ❏ susceptible, ❏ resistant 
S: ❏ susceptible, ❏ resistant 
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Any resistance: ❏ no, ❏ yes 
MDR: ❏ no, ❏ yes 
Inno-Lipa for R resistant strains only: ❏ susceptible, ❏ resistant 
Inno-Lipa pattern________________________________________________ 
RFLP:  
Clustered strain: ❏ no, ❏ yes 
Number of IS6110 copies__________ 
